Document:

Exhibit 10.9

 

Certain portions of this exhibit have been omitted pursuant to
Rule 601(b)(10) of Regulation S-K The omitted information is (i) not material and (ii) would likely cause competitive harm to Blue Water
Vaccines, Inc. if publicly disclosed. Information that has been omitted has been noted in this document with a placeholder identified
by the mark “[***]”.

 

DATED

16th July 2019

 

 (1) OXFORD UNIVERSITY INNOVATION LIMITED

 

and

 

 (2) BLUE WATER VACCINES INC.

 

LICENCE OF TECHNOLOGY

(OUI PROJECT Nos. 13709, 16867,
16870 and 16872)

 

    1

     

    

 

THIS AGREEMENT is made on

 

BETWEEN:

 

	(1)	OXFORD UNIVERSITY INNOVATION LIMITED (Company No. 2199542) whose registered office
is at University Offices, Wellington Square, Oxford OXl 2JD, England (“QUI”); and

 

	(2)	BLUE WATER VACCINES INCORPORATED (Company Registration No.) whose registered office
is at 1013 Centre Rd, Suite 403-B New Castle Wilmington Delaware 19805 USA (the “Licensee”).

 

BACKGROUND:

 

The Licensed Technology is connected
with QUI Project Numbers: 13709, 16867, 16870 and 16872 which comprise components from the Haemagglutinin proteins of Influenza A Group
1, Influenza Group 2 and Influenza B and a VLP delivery system which together form a candidate Universal Influenza vaccine. The Licensee
wishes to acquire a licence to the Licensed Technology and QUI is willing to license the Licensed Technology to the Licensee, on the terms
of this agreement.

 

AGREEMENT:

 

	1.	Interpretation

 

In this
agreement (including its Schedules), any reference to a “clause” or “Schedule” is a reference to a clause of this
agreement or a schedule to this agreement, as the case may be. Words and expressions used in this agreement have the meaning set out in
Schedule 1.

 

	2.	Condition Precedent

 

	2.1	The Licence and all obligations of the parties under this agreement (other than
the obligations set out in Clause ) are conditional upon the Licensee entering into an agreement with the University to provide funding
for 3 years’ salary for Dr Craig Thompson in the University’s Department of Zoology (minimum of £420,000 to be pre-paid to the University
in advance or placed in escrow) to be paid by 31st December 2019

 

	2.2	If this condition has not been satisfied or waived on or before 5 p.m. on 31st
December 2019 (or such later time and date as is agreed by QUI), this agreement shall be rendered null and void; except that the parties
agree that confidentiality provisions in clause 8 will continue in full force and effect in accordance with 12.8 all of the obligations
of the parties under this agreement shall cease and no party shall have any licence, right or claim against any other party under this
agreement.

 

	3.	Grant of Licence

 

	3.1	In consideration of the payments required to be made under this agreement by the
Licensee QUI grants to the Licensee a licence in the Territory in respect of the Licensed Technology in the Field to develop, make, have
made, use and have used and Market the Licensed Product on and subject to the terms and conditions of this agreement. Subject to clause
5, the Licence is exclusive in the Field in relation to the Licensed Intellectual Property Rights. The Licence is non exclusive in relation
to the Licensed Kno w-How. QUI retains unrestricted rights to use and license others to use the Licensed
Know-How, and to use and license the Licensed Technology outside the Field.

 

    2

     

    

 

	3.2	As soon as is reasonably possible after the date of this agreement, OUI will,
at QUl’s cost, supply the Licensee with the Documents.

 

	3.3	The Licensee may grant sub-licences with the prior written consent of QUI, such
consent not to be unreasonably withheld, provided that:

 

 (a) the sub-licensee has obligations to the Licensee commensurate with those which the Licensee has to QUI under this agreement, except where it is not legally possible to include such obligations in the sub-licence; and

 

(bl the
nature of the proposed sub-licensee is not likely in OUl’s opinion to have any detrimental impact on the reputation of either QUI or of
the University; and

 

(cl immediately
following the grant of each sub-licence, the Licensee provides a certified copy of that sub-licence to OUI; and

 

(d) no sub-licence will carry any
right to sub-sub-license.

 

	4.	Additional Applications and Improvements

 

	4.1	The Applications will include the Additional Applications once those projects have
been assigned by the University to OUI and all references to the Applications throughout the agreement will include the Additional Applications.

 

	4.2	The Licensed Technology covered by the Licence in clause 2 includes Inventor Improvements.
QUI will communicate in writing to the Licensee within a reasonable time all Inventor Improvements.

 

	4.3	The Licensee acknowledges and agrees that all Intellectual Property Rights in Inventor
Improvements belong to QUI.

 

	4.4	The Licensee will communicate in writing to QUI within a reasonable time all Licensee
Improvements.

 

	4.5	QUI acknowledges and agrees that all Intellectual Property Rights in the Licensee
Improvements belong to the Licensee.

 

	5.	Rights Re Non-Commercial Use

 

	5.1	The Licensee grants QUI an irrevocable, perpetual, royalty-free licence to grant
the University and those persons who at any time work or have worked on the Licensed Technology the licence set out in clause 5.2.

 

	5.2	QUI has granted and, in respect of Licensee Improvements, will grant, to the University
and those persons who at any time work or have worked on the Licensed Technology a non transferable, irrevocable, perpetual, royalty-free
licence to use and publish the Licensed Technology and the Licensee Improvements for Non-Commercial Use.

 

    3

     

    

 

	6.	Filing and Maintenance

 

	6.1	The Licensee will pay OUI the Past Patent Costs representing the Licensee’s sole
                                                       contribution to the patent costs incurred by OUI prior to the parties entering into this agreement, within thirty (30) days of receiving an invoice from OUI.

 

	6.2	QUI will, in consultation with the Licensee and at the Licensee’s cost, prosecute,
use all reasonable endeavours to maintain, and renew the Applications throughout the duration of this Licence Agreement. The Licensee
will reimburse OUI for all costs, filing fees, lawyers’ and patent agents’ fees, expenses and outgoings of whatever nature incurred by
OUI in the prosecution, maintenance and renewal of the Applications (including those incurred in opposition proceedings before the European
Patent Office or in ex parte re-examination or inter partes review proceedings in the United States Patent and Trademark Office (“USPTO”)
or any similar proceedings before any patent office challenging the grant or validity of the Applications) within thirty (30) days of
receiving an invoice from OUI. OUI shall be entitled to make it a condition of any action of OUI under this clause 6.2 that the Licensee
provides QUI with sufficient money in advance to cover the costs likely to be incurred in the action.

 

	6.3	Where the Applications are prosecuted in the USPTO and the Licensee is a small
business concern as defined under the US Small Business Act (15USC632) QUI intends to pay reduced USPTO patent fees under US patent law
3SUSC 41(h)(l). The Licensee will notify OUI as soon as reasonably possible if it or a sub-licensee ceases to be a small business concern
as defined under the US Small Business Act (1SUSC632) or becomes aware of any other reason why it would not qualify for reduced USPTO
patent fees under US patent law 35USC 41(h)(l).

 

	6.4	The Licensee shall inform QUI not less than six (6) months in advance of the National
Phase filing deadline (noted in Schedule 2) of the territories within the scope of the PCT that it wishes to be covered in the National
Phase of that Application. In the event that the Licensee does not give the required minimum of six months advance notice QUI shall then
be entitled to proceed with filing the Applications at the licensee’s cost in whichever territories as it may in its sole discretion decide.

 

	6.5	The Licensee shall be entitled to remove any one or more of the countries from
the Territory at any time by giving not less than six months notice to OUI. If an Application is proceeding under the PCT then such notice
may not be given any earlier than the date for commencement of the National Phase filing. For the avoidance of doubt the Licensee shall
remain liable for the costs mentioned in clause 6.2 that arise or are incurred by OUI during the said notice period in respect of the
countries being removed.

 

	7.	Infringement

 

	7.1	Each party will notify the other in writing of any misappropriation or infringement
of any rights in the licensed Technology of which the party becomes aware.

 

	7.2	The licensee has the first right (but is not obliged) to take Legal Action at
its own cost in relation to any misappropriation or infringement of any rights included in the Licensed Intellectual Property Rights in
the Field. The Licensee must discuss any proposed Legal Action with OUI prior to the Legal Action being commenced, and take due account
of the legitimate interests of OUI in the Legal Action it takes.

 

    4

     

    

 

	7.3	If the Licensee takes Legal Action under clause 7.2, the Licensee will:

 

		7.3.1	indemnify and hold OUI and the University harmless against
all costs (including lawyers’ and patent agents’ fees and expenses), claims, demands and liabilities arising out of or consequent upon
a Legal Action and will settle any invoice received from QUI in respect of such costs, claims, demands and liabilities within thirty
(30) days of receipt; and

 

		7.3.2	treat any account of profits or damages (including, without
limitation, punitive damages) awarded in or paid to the Licensee under any settlement ofthe Legal Action as Net Sales for the purposes
of clause 8, having first for these purposes deducted from the award or settlement an amount equal to any legal costs incurred by the
Licensee in the Legal Action that are not covered by an award of legal costs; and
	 	 	 

		7.3.3	keep QUI regularly informed of the progress of the Legal
Action, including, without limitation, any claims affecting the scope of the Licensed Technology.

 

	7.4	QUI may take any Legal Action at its own cost in relation to any misappropriation
or infringement of any rights included in the Licensed Intellectual Property Rights where:
	 	 

		7.4.1	the Licensee has notified QUI in writing that it does not intend to take any Legal
Action in relation to any misappropriation or infringement of any such rights; or
	 	 	 

		7.4.2	if having received professional advice with regard to any Legal Action within
                                                                                                                                                                         fourteen (14)
days of the notification under clause 7.1, and consulted with QUI, the Licensee does not take reasonable steps to act upon an agreed
process for dealing with such misappropriation or infringement (which may include, for the avoidance of doubt, seeking a second
opinion in respect of such professional advice) within any timescale agreed between OUI and the Licensee and in any event within
forty-five (45) days of notification under clause 7.1, provided it shall not settle any action without first consulting with the
Licensee and taking account of the reasonable observations and requests of the Licensee.

 

	7.5	Subject to clauses 7.2 and 7.3, if the Licensee takes Legal Action QUI will provide
such reasonable assistance as requested by the Licensee in relation to such Legal Action at the Licensee’s cost, provided that the Licensee
indemnifies QUI under clause 7.3 for the costs of any legal representation in the Legal Action required by QUI.

 

	8.	Confidentiality

 

	8.1	Subject to clauses 8.2, Error! Reference source not found. and 8.4, each party
(being a receiving or disclosing party as the case may be) will keep confidential the Confidential Information of the other party and
will not disclose or supply the Confidential Information to any third party or use it for any purpose, except in accordance with the terms
and objectives of this agreement.

 

	8.2	The Licensee may disclose to sub-licensees of the Licensed Technology such of
the Confidential Information of which it consists as is necessary for the exercise of any rights sub-licensed, provided that the Licensee
shall ensure that such sub-licensees accept a continuing obligation of confidentiality in the same terms as this clause, and giving third
party enforcement rights to OUI, before the Licensee makes any disclosure ofthe Confidential Information.

 

	8.3	Confidential Information may be exchanged freely between QUI and the University
and communications between those two parties shall not be regarded as disclosures, dissemination or publication for the purpose of this
agreement. QUI may also disclose the terms of this agreement and royalty reports and payments made by the Licensee to any third parties
that have rights to a revenue share for
providing funding in the development of the Licensed Technology.

 

    5

     

    

 

	8.4	Clause 8.1 will not apply to any Confidential Information which:

 

		8.4.1	is known to the receiving party before disclosure, and not
subject to any obligation of confidentiality owed to the disclosing party;
	 	 	 

		8.4.2	is or becomes publicly known without the fault ofthe receiving
party;
	 	 	 

		8.4.3	is obtained by the receiving party from a third party in
circumstances where the receiving party has no reason to believe that it is subject to an obligation of confidentiality owed to the disclosing
party;
	 	 	 

		8.4.4	the receiving party can establish by reasonable proof was
substantially and independently developed by officers or employees of the receiving party who had no knowledge of the disclosing party’s
Confidential Information; or
	 	 	 

		8.4.5	is approved for release in writing by an authorised representative
of the disclosing party.

 

	8.5	Nothing in this agreement will prevent a party from disclosing Confidential Information
where it is required to do so by law or regulation or by order of a court or competent authority, provided that, in the case of a disclosure
under the Freedom of Information Act 2000 (“FOIA”), none of the exemptions in the FOIA applies to the relevant Confidential
Information.

 

	8.6	If either party to this agreement receives a request under the FOIA to disclose
any information that, under this agreement, is the other party’s Confidential Information, it will notify and consult with the other party.
The other party will respond within five (5) days after receiving notice if that notice requests the other party to provide information
to assist in determining whether or not an exemption under the FOIA applies to the information requested under the FOIA.

 

	9.	Royalties and Other Payments

 

	9.1	OUI will invoice the Licensee for the Signing Fee shortly after signature of this
agreement and the Licensee must settle the invoice within thirty (30) days of receipt.

 

	9.2	The Licensee will pay to OUI a royalty equal to the Royalty Rate on all Net Sales
of Licensed Products. The Licensee will also pay to OUI a royalty equal to the Royalty Rate on any sums received from a sub-licensee to
meet an obligation under the terms of a sub-licence to pay a minimum sum over and above the actual royalties due to be paid by that sub-licensee
on sales of Licensed Products.

 

	9.3	Following expiration or revocation of the last Valid Claim covering a Licensed
Product is Marketed the Step Down Royalty Rate shall apply to such Licensed Products.

 

	9.4	In the event that the royalties paid to OUI under clause 9.2 do not amount to
at least the Minimum Sum, the Licensee must make up the difference between the royalties paid under clause 9.2 and the Minimum Sum in
each Licence Year where a Minimum Sum applies.

 

    6

     

    

 

	9.5	The Licensee will pay to OUI a royalty equal to the Fee Income Royalty Rate on all up-front, milestone
and other one-off payments (other than payments made solely in relation to research provided by the Licensee) received by the Licensee
under or in connection with all sub-licences and other contracts granted by the Licensee with respect to the Licensed Technology. The
Licensee will pay each such royalty within thirty (30) days after its receipt of the payment to which the royalty relates.

 

	9.6	The licensee will notify QUI as soon as possible after it or any sub-licensee
achieves any Milestone, and pay to OUI the Milestone Fee in respect of each Milestone within thirty (30) days of the date on which each
Milestone is achieved by the Licensee or a sub-licensee.

 

	9.7	The Signing Fee and the Milestone Fee are non-refundable and will not be considered
as an advance payment on royalties payable under clause 9.2. No part of the Minimum Sum will be refundable or applicable to succeeding
Licence Years.

 

	9.8	The Minimum Sum and the Milestone Fee will be indexed to the RPI and each Minimum
Sum and Milestone will be increased (or decreased, if appropriate) by the percentage change in the RPI between the date of this agreement
and:

 

		(a)	in the case of any Minimum Sum, the last day of the Licence Vear to which it relates; and
	 	 	 

		(b)	in the case of any Milestone Fee, the date on which the Milestone to which it relates is achieved.

 

	9.9	The licensee may supply a commercially reasonable quantity of licensed Products
for promotional sampling provided that the number of Licensed Products supplied for promotional sampling shall not be greater than 5%
of total number of units of each Licensed Product sold leased or licensed by the Licensee in any Quart er. Except as set out in this clause,
the Licensee must not accept or solicit any non-monetary consideration when Marketing Licensed Products or when issuing sub-licences of
the Licensed Technology without the prior written consent of QUI.

 

	9.10	The licensee will make all payments in pounds sterling or any currency replacing
pounds sterling in its entirety.

 

	9.11	For the purposes of calculating any amount payable by the Licensee to OUI in a
currency other than pounds sterling (or replacement currency), the Licensee shall apply an exchange rate equivalent to the average of
the applicable closing mid rates quoted by the Financial Times as published in London on:

 

		(a)	the first Business Day of each month during the quarter just closed; or
	 	 	 

		(b)	for payments under clause 9.5 only, the first Business Day of the month in which the payment was received
by the Licensee.

 

	9.12	Where the Licensee has to withhold tax by law, the Licensee will deduct the tax,
pay it to the relevant taxing authority, and supply OUI with a Certificate of Tax Deduction at the time of payment to OUI.

 

	9.13	In the event that full payment of any amount due from the Licensee to OUI under
this agreement is not made by any of the dates stipulated, the Licensee shall be liable to pay interest on the amount unpaid at the rate
of eight per cent (8%) per annum over the base rate for the time being of Barclays Bank pie. Such interest shall accrue on a daily basis
from the date when payment was due until the date of actual payment of the overdue amount, whether before or after judgment, and shall be compounded quarterly.

 

    7

     

    

 

	9.14	If the Licensed Product is of a description covered by the Medicines Access Policy,
the Licensee shall adhere to the requirements ofthe Medicines Access Polic y.

 

	10.	Best Endeavours

 

	10.1	The Licensee must use its best endeavours to develop, exploit and Market the Licensed
Technology to maximise the financial return for both parties.

 

	10.2	The Licensee must use its best endeavours to develop, exploit and Market the Licensed
Technology in accordance with the Development Plan .

 

	11.	Royalty Reports and Audit

 

	11.1	The Licensee will provide OUI with a report at least once in every six (6) months
detailing the activities and achievements in its development of the Licensed Technology in order to facilitate its commercial exploitation,
and in the development of potential Licensed Pro ducts.

 

	11. 2	 The Licensee will provide OUI with a royalty report within
thirty (30) days after the close of each Quarter for each Licensed Product Marketed by the Licensee and its sub-licensees. Each Royalty
Report will:

 

		(al	set out the Net Sales of each Licensed Product Marketed by
the Licensee and any sub licensees, including the total gross selling price of each Licensed Product Marketed by the Licensee and any
sub-licensees and the quantity or total number of units of each Licensed Product Marketed by the Licensee and any sub-licensees;

		(b)	set out details of deductions made in the calculation of
Net Sales from the invoiced price of each Licensed Product in the form in which it is Marketed by the Licensee or any sub licensees;

		(c)	set out details of the quantity of Licensed Products used
for promotional sampling by the Licensee or any sub-licensees;

		(d)	set out details of any deductions made under clause 10.4
below;

		(el	provide a calculation of the royalties due;

		(f)	set out details of payments received by the Licensee to which the Fee Income Royalty Rate applies and
provide a calculation of the royalties due;

		(g)	provide a statement showing whether or not royalties due exceed the Minimum Sum and, if so, by how much;

		(h)	set out details of Milestones achieved by the Licensee or any sub-licensees; and

		(i)	set out the steps taken during the Licence Year to promote and Market Licensed Produ cts.

 

The Licensee must pay OUI the
royalties due in respect of the Quarter just closed at the same time as the Licensee delivers the Royalty Report.

 

    8

     

    

 

	11.3	The Licensee will deliver to OUI a periodic report at the close of each Licence Year providing sufficient
data (in outline form) to give a reasonable indication or estimate of the actual or expected market share of the Licensee and its sub-licensees
and will notify OUI in the event that its market share does or is expected to breach the limits set out in the 2014 Commission Regulation
316/2014 Technology Transfer Block Exemption Regulation and Guidelines in Commission Communication 2014/c 89/03 and any successor regulation.
This obligation is not intended to place a significant additional financial burden on the Licensee.

 

	11.4	If the Licensee has to pay royalties to a third party (other than an Affiliate),
for the right to use a proprietary manufacturing process or proprietary adjuvants in order to make or have made a Licensed Product, under
a licence of Intellectual Property Rights without which the Licensed Technology cannot be lawfully exploited, then the Licensee will be
entitled to deduct from all payments due to OUI at the Royalty Rate on Net Sales of Licensed Products in respect of the products concerned
an amount equal to fifty per cent (50%) of the royalties actually paid to that third party, up to a maximum amount of twenty-five percent
(25%) of the royalties due to OUI.

 

	11.5	If a Licensed Product Marketed by the Licensee is re-Marketed by an Affiliate
or an entity over which the Licensee exercises Control, the royalty on each such Licensed Product will be calculated on the highest of
the prices at which it is Marketed or re-Marketed.

 

	11.6	The Licensee must keep complete and proper records and accurate accounts of all
Licensed Products used and Marketed by the Licensee and any sub-licensee in each Licence Year for at least six (6) years. OUI may, through
an independent certified accountant appointed by OUI (“the Auditor”), audit all such accounts on at least thirty (30) days’
written notice no more than once each Licence Year for the purpose of determining the accuracy of the Royalty Reports and payments. The
Auditor shall be:

 

		11.6.1	permitted by the Licensee to enter the Licensee’s principal
place of business upon reasonable notice to inspect such records and accounts;
	 	 	 

		11.6.2	entitled to take copies of or extracts from such records
and accounts;
	 	 	 

		11.6.3	given all other information by the Licensee as may be necessary
or appropriate to enable the amount of royalties payable to be ascertained including the provision of relevant records; and
	 	 	 

		11.6.4	shall be allowed access to and permitted to conduct interviews
of any sales, engineering or other staff of the Licensee in order to verify the accuracy of the records and accounts and the accuracy
of any statements provided to OUI under clause 11.2.

If on any
such audit a shortfall in payments of greater than two percent (2%) is discovered by the Auditor in respect of the audit period, the Licensee
shall pay OUl’s audit costs.

 

	11.6	●The auditing rights and obligations on the Licensee
set out in clause 11.6 will apply equally to any sublicenses allowed for in this agreement and the Licensee will ensure that the same
obligations and access rights allowing OUI auditing rights to the sub-licensee are included in each sub licence agreement.

 

	12.	Duration and Termination

 

	12.1	Subject to clause 2, this agreement will take effect on the date of signature.
Subject to the possibility of earlier termination under the following provisions of this clause 12, and subject to the possibility of
an extension to the term by mutual agreement, this agreement shall continue in force until the expiry of ten years following the last
to expire of all patents and patent applications within the definition of the Application.

 

    9

     

    

 

	12.2	If either party commits a material breach of this agreement, and the breach is
not remediable or (being remediable) is not remedied within the period allowed by notice given by the other party in writing calling on
the party in breach to effect such remedy (such period being not less than thirty (30) days), the other party may terminate this agreement
by written notice having immediate effect.

 

	12.3	The Licensee may terminate this agreement for any reason at any time provided it
                                                      gives QUI six (6) months’
written notice to terminate expiring after the third anniversary of this agreement whereupon the Licensee shall bring all sub-licences
to an end on the same date. Any such termination shall not absolve the Licensee of its obligation to accrue and pay royalties and other
payments under the provisions of clause 9 in respect of the period prior to termination.

 

	12.4	QUI may terminate this agreement:

 

		(a)	immediately, if the Licensee has a petition presented for
its winding-up, or passes a resolution for voluntary winding-up otherwise than for the purposes of a bona fide amalgamation or reconstruction,
or compounds with its creditors, or has a receiver administrator or administrative receiver appointed of all or any part of its assets,
or enters into any arrangements with creditors, or takes or suffers any similar action in consequence of debts;

 

		(b)	on thirty (30) days’ written notice if:

		(i)	the Licensee opposes or challenges the validity of the Application or raises the
claim that the Know-How is not necessary to develop and Market Licensed Products; or

		(ii)	in OUl’s reasonable opinion, the Licensee is taking insufficient or inadequate
steps to develop or Market the Licensed Products and the Licensee does not take any further steps requested by QUI by written notice within
a reasonable time.

 

	12.5	On termination or expiration of this agreement, for whatever reason, the Licensee:

 

		(a)	must bring all sub-licences to an end on the same date;

		(b)	shall pay to OUI all outstanding royalties and other sums
due under this agreement;

		(c)	shall provide OUI with details of the stocks of Licensed
Products held at the point of termination;

		(d)	must cease to use or exploit the Licensed Technology, provided
that this restriction does not apply to Licensed Know-How which has entered the public domain through no fault of the Licensee, and that
the Licensee may continue to use the Licensed Technology in order to meet any specific existing binding commitments already made by the
Licensee at the date of termination and requiring delivery of Licensed Products within the next six (6) months;

		(e)	must, at the option of QUI and at the Licensee’s cost, destroy
all other Licensed Products or send all other Licensed Products to a location nominated by OUI to the Licensee in writing; and

		(f)	grants OUI an irrevocable, transferable, non-exclusive licence
to develop, make, have made, use and Market the Licensee’s Improvements and products that incorporate, embody or otherwise exploit the
same. OUI shall pay a reasonable royalty for use of this licence unless the termination arises under clause 12.4, or is by QUI under
clause 12.2, in which case it shall be royalty-free.

 

    10

     

    

 

 

	12.6	Termination of this agreement, whether for breach of this agreement or otherwise,
shall not absolve the Licensee of its obligation to accrue and pay royalties under the provisions of clause 8 for the duration of any
notice period and in respect of any dealings in Licensed Products permitted by clause 12.5 or to reimburse OUI for all costs, filing fees,
lawyers’ and patent agents’ fees, expenses and outgoings of whatever nature incurred by OUI in the prosecution, maintenance and renewal
of the Application duration of any notice period in accordance with clause 6.2.

 

	12.7	Clauses 1, 5.2, 7.3, 12.5, 12.7, 12.8, 13, 14.4 and 14.14 will survive the termination
or expiration of this agreement, for whatever reason, indefinitely.

 

	12.8	Clauses 8 and 11.6 will survive the termination or expiration of this agreement,
for whatever reason, for a period of six (6) years.

 

	13.	Liability

 

	13.1	To the fullest extent permissible by law, OUI does not make any warranties of any
kind including, without limitation, warranties with respect to:

		(a)	the quality of the Licensed Technology;

		(bl	the suitability of the Licensed Technology for any particular
use;

		(cl	whether use of the Licensed Technology will infringe third-party
rights; or

		(dl	whether the Applications will be granted or the validity
of any patent that issues in response to those Applications.

 

	13.2	The Licensee agrees to indemnify OUI and the University and hold OUI and the University
harmless from and against any and all claims, damages and liabilities:

		(a)	asserted by third parties (including claims for negligence)
which arise directly or indirectly from the use of the Licensed Technology or the Marketing of Licensed Products by the Licensee and/or
its sub-licensees; and/or

		(bl	arising directly or indirectly from any breach by the Licensee
of this agreement.

 

	13.3	OUI will use reasonable endeavours to defend any Indemnified Claim or (at OUl’s
option) allow the Licensee to do so on its behalf (subject to the University retaining the right to be kept informed of progress in the
action and to have reasonable input into its conduct.) QUI will not (except as required by law) make any admission, compromise, settlement
or discharge of any Indemnified Claim without the consent of the Licensee (which will not be unreasonably withheld or delayed).

 

	13.4	The Licensee undertakes to make no claim against any employee, student, agent
or appointee of OUI or of the University, being a claim which seeks to enforce against any of them any liability whatsoever in connection
with this agreement or its subject-matter.

 

	13.5	Subject to clause 13.7 and except in relation to the indemnities in clause 7.3
and 13.2, the liability of either party for any breach of this agreement, in negligence or arising in any other way out of the subject-matter
of this agreement, will not extend to incidental or consequential damages or to any loss of profits.

 

    11

     

    

 

	13.6	Subject to clause 13.7, the liability of OUI to the Licensee accruing in any Licence
Year under or otherwise in connection with this agreement or its subject-matter, including without limitation liability for negligence,
shall in no event exceed:
	 	 

		(al	in respect of liability accruing in the first Licence Year,
the amount of the Signing Fee paid to OUI; and
	 	 	 

		(bl	in respect of liability accruing in any subsequent Licence
Year, the total royalties paid in the previous Licence Year to OUI under clause 9.2.

 

	13.7	Nothing in this agreement shall limit or exclude any liability for fraud or fraudulent
misrepresentation or death, or personal injury or any other liability which may not, by law, be excluded.

 

	14.	General

 

	14.1	Registration - The licensee must register its interest in the Licensed Technology
with any relevant authorities in the Territory as soon as legally possible. The Licensee must not, however, register an entire copy of
this agreement in any part of the Territory or disclose its financial terms without the prior written consent of OUI.

 

	14.2	Advertising - The Licensee must not use the name of OUI, the University or the
Inventors in any advertising, promotional or sales literature, without OUl’s prior written approval.

 

	14.3	Packaging - The Licensee will ensure that the Licensed Products and the packaging
associated with them are marked suitably with any relevant patent or patent application numbers to satisfy the laws of each of the countries
in which the Licensed Products are sold or supplied and in which they are covered by the claims of any patent or patent application, to
the intent that CUI shall not suffer any loss or any loss of damages in an infringement action.

 

	14.4	Thesis - This agreement shall not prevent or hinder registered students of the
University from submitting for degrees of the University theses based on the Licensed Technology; or from following the University’s procedures
for examinations and for admission to postgraduate degree status.

 

	14.5	Taxes - Where the licensee has to make a payment to OUI under this agreement which
attracts value-added, sales, use, excise or other similar taxes or duties, the Licensee will be responsible for paying those taxes and
duties.

 

	14.6	Notices - All notices to be sent to CUI under this agreement must indicate the
CUI Project N!:! and should be sent, by post and fax unless agreed otherwise in writing, until further notice to: The Managing Director,
Oxford University Innovation Ltd, Buxton Court, 3 West Way, Oxford OX2 OJB, Fax: +44 (0)1865 280831. All notices to be sent to the Licensee
under this agreement should be sent, until further notice, to the Licensee’s Contact and Address indicating the OUI Project N!!.

 

	14.7	Force Majeure - If performance by either party of any of its obligations under
this agreement (not including an obligation to make payment) is prevented by circumstances beyond its reasonable control, that party will
be excused from performance of that obligation for the duration of the relevant event.

 

    12

     

    

 

	14.8	Assignment - The Licensee may not assign any of its rights or obligations under
this agreement in whole or in part, except to an Affiliate and only for so long as it remains an Affiliate, without the prior written
consent of QUI. Assignment, for these purposes, includes the acquisition of Control of the Licensee by a third party. If QUI assigns its
rights in the Licensed Technology to any person it shall do so expressly subject to the licensee’s rights under this Agreement.

 

	14.9	Severability - If any of the provisions of this agreement is or becomes invalid,
illegal or unenforceable, the validity, legality or enforceability of the remaining provisions will not in any way be affected or impaired.
The parties will, however, negotiate to agree the terms of a mutually satisfactory provision, achieving as nearly as possible the same
commercial effect, to be substituted for the provision found to be void or unenforceable.

 

	14.10	No Partnership etc - Nothing in this agreement creates, implies or evidences any
partnership or joint venture between QUI and the Licensee or the relationship between them of principal and agent.

 

	14.11	Entire Agreement - This agreement constitutes the entire agreement between the
parties in relation to the Licence to the exclusion of all other terms and conditions (including any terms or conditions which the licensee
purports to apply under any purchase order, confirmation order, specification or other document). The Licensee has not relied on any other
statements or representations in agreeing to enter this agreement and waives all claims for breach of any warranty and all claims for
any misrepresentation, (negligent or of any other kind, unless made by QUI fraudulently) in relation to any representation which is not
specifically set out in this agreement. Specifically, but without limitation, this agreement does not impose or imply any obligation on
QUI or the University to conduct development work. Any arrangements for such work must be the subject of a separate agreement between
the University and the Licensee.

 

	14.12	Variation - Any variation of this agreement must be in writing and signed by authorised
signatories for both parties. For the avoidance of doubt, the parties to this agreement may rescind or vary this agreement without the
consent of any party that has the benefit of clause 14.14.

 

	14.13	Waiver - No failure or delay by either party in enforcing its rights under this
agreement, or at law or in equity will prejudice or restrict those rights. No waiver of any right will operate as a waiver of any other
or later right or breach. Except as stated to the contrary in this agreement, no right, power or remedy conferred on, or reserved to,
either party is exclusive of any other right, power or remedy available to it, and each of those rights, powers, and remedies is cumulative.

 

	14.14	Rights Of Third Parties - The parties to this agreement intend that by virtue
of the Contracts (Rights of Third Parties) Act 1999 the University and the people referred to in clause 13.4 will be able to enforce the
terms of this agreement intended by the parties to be for their benefit as if the University and the people referred to in clause 13.4
were party to this agreement.

 

	14.15	Governing Law - This agreement is governed by English Law, and the parties submit
to the exclusive jurisdiction of the English Courts for the resolution of any dispute which may arise out of or in connection with this
agreement except in relation to any action in relation to Intellectual Property Rights or Confidential Information which may be sought
in any court of competent jurisdiction.

 

    13

     

    

 

Schedule 1

 

DEFINITIONS

(Clause
1}

 

Academic
and Research Purposes means research, teaching or other scholarly use which is undertaken for the purposes of education and research.

 

Affiliate means any company or legal
entity in any country Controlling or Controlled by the Licensee.

 

Applications means:

 

		(a)	the patent applications set out in Schedule 2 and any further applications notified
by OUI to the Licensee that are filed by OUI for covering Influenza A Group 2 and Influenza B that name any of the Inventors as inventors
in the application;

		(bl	any patents granted in response to those applications;

		(c)	any corresponding foreign patents and applications which may be granted to OUI
in the Territory based on and deriving priority from that application; and

		(d)	any addition, continuation, continuation-in-part, division, reissue, renewal or
extension based on the Applications.

 

Business
Day means a day, other than a Saturday or Sunday, on which clearing banks are permitted to open in London.

 

Clinical
Patient Care means diagnosing, treating and/or managing the health of persons under the care of an individual having the right to use
the Licensed Technology in the event that such Licensed Technology is capable of application in a healthcare setting without further development.

 

Confidential Information means
in relation to each party any materials, trade secrets or other information disclosed by that party to the other, including, without limitation:

 

		(a)	the Licensed Technology, to the extent that it is not disclosed by the Application when published;
and

		(b)	this agreement.

 

Control means:

 

		(a)	ownership of more than fifty percent (50%) of the voting share capital of the relevant entity; or

		(b)	the ability to direct the casting of more than fifty percent (50%) of the votes exercisable at a general
meeting of the relevant entity on all, or substantially all, matters.

 

Development Plan means the plan set out in Schedule 3.

 

Documents
means the documents and materials set out in Schedule 2. Fee Income Royalty Rate means the royalty rate set out in Schedule 2. Field means
the field set out in Schedule 2.

 

Improvement
means any development of the Licensed Technology which would, if commercially practised, infringe and/or be covered by a claim subsisting
or being prosecuted in the Application.

 

    14

     

    

 

Indemnified
Claim means any claim under which OUI and the University are entitled to be indemnified under clause 13.2.

 

Intellectual
Property Rights means patents, trade marks, copyrights, database rights, rights in designs, and all or any other intellectual or industrial
property rights, whether or not registered or capable of registration.

 

Inventor means the inventor or inventors named in the Application
and identified in Schedule 2.

 

Inventor
Improvements means any Improvements made prior to the second anniversary of the date of this agreement solely by the Inventor within the
Field, and the Intellectual Property Rights pertaining to them, of which OUI has been made aware and is legally able to license.

 

Legal
Action means commencing or defending any proceedings before a court or tribunal in any jurisdiction in relation to any rights included
in the Licensed Intellectual Property including all claims and counterclaims for infringement and for declarations of non-infringement
or invalidity.

 

Licence means the licence granted by OUI to the Licensee
under clause 3.1.

 

Licensed
Intellectual Property Rights means the Application and (to the extent they constitute Intellectual Property Rights) OUl’s Improvements.

 

Licensed
Know-how means all confidential information relating to the Application that has been communicated to the Licensee by OUI in writing before
the date of this agreement or is communicated in writing to the Licensee by OUI under this agreement and within twelve (12) months after
the date of this agreement and (to the extent they constitute confidential information) Inventor Improvements.

 

Licensed
Product means any product, process, service or composition which is entirely or partially produced by means of or with the use of, or
within the scope of, the Licensed Technology, or any of it.

 

Licensed
Technology means the Licensed Intellectual Property Rights and the Licensed Know-How, and such (if any) other Intellectual Property Rights
owned by or licensed to OUI as may be specifically identified in Schedule 2 (to the extent, in the case of licensed rights, that OUI is
legally able to grant a sub-licence of the same).

 

Licensee’s
Contact and Address means the address for the Licensee set out in Schedule 2 of this agreement.

 

Licensee
Improvements means any Improvements made prior to the second anniversary of the date of this agreement by the Licensee, and the Intellectual
Property Rights pertaining to them.

 

Licence
Year means each twelve {12) month period beginning on the date of this agreement and each anniversary of the date of this agreement.

 

 

Market
means, in relation to a Licensed Product, offering to sell, lease, licence or otherwise commercially exploit the Licensed Product or the
sale, lease, licence or other commercial exploitation of the Licensed Product.

 

    15

     

    

 

 

Medicines
Access Policy means the policy of the University to promote access to pharmaceutical and other products and services, the current version
of which is available at htt ps:// researchsu pport.admin.ox.ac.uk/ policv/ oxford/ medicines.

 

Milestone
and Milestone Fee means the milestones, and the amounts payable on achievement of each of the milestones, set out in Schedule 2.

 

Minimum Sum means the minimum sum or sums set out in Schedule
2.

 

Net Sales means the gross
selling price of the licensed Product in the form in which it is Marketed by the licensee or any sub-licensee, less:

 

		(a)	trade, quantity or cash discounts actually given; and

		(b)	outbound carriage and packaging expenses actually paid; and

		(c)	customs duties, sales taxes or other taxes imposed upon and paid with respect to such sales (excluding
personal taxes).

 

Non-Commercial
Use means Academic and Research Purposes and the purposes of Clinical Patient Care. This includes the right for the University to license
the Licensed Technology to any of its collaborators in connection with and solely for the University’s Academic and Research Purposes;
but it does not include the right to grant any license to commercially exploit the Licensed Technology.

 

Past Patent Costs means the past patent costs set out in
Schedule 2.

 

Project means the project referred to in BACKGROUND.

 

Quarter means each period of three
calendar months during a Licence Year with the first Quarter commencing on the first day of each Licence Year.

 

RPI means the Retail Prices
Index for all items which is published in the United Kingdom by the Office for National Statistics, or any replacement of it.

 

Royalty Rate means the royalty rate or rates set out in
Schedule 2.

 

Royalty Report means the report to be prepared by the Licensee
under clause 11.2.

 

Signing Fee means the signing fee set out in Schedule 2.

 

Step-Down Royalty Rate means the royalty rate or rates set
out in Schedule 2.

 

Territory means the territory
or territories set out in Schedule 2, excluding any territory or territories removed through the operation of clause 6.3.

 

University means the Chancellor,
Masters and Scholars of the University of Oxford whose administrative offices are at the University Offices, Wellington Square, Oxford
OXl 2JD.

 

Valid Claim
means a granted or currently pending claim included in the Applications that has not expired nor been held permanently revoked, unpatentable,
invalid or unenforceable by a court or tribunal of competent jurisdiction in a final and non-appealable judgment; nor been rendered unenforceable
through disclaimer or otherwise abandoned.

 

    16

     

    

 

Schedule 2

 

	Applications:	 	OUI project 13709: Influenza A haemagglutinin antigen Group 1 (Hl)

                         - site of limited variability

	 	 	 
	 	 	International Patent Application
No. PCT/GB2017 /052510, which was filed on 25th August 2017 entitled “lmmunogenic composition”
	 	 	 
	

Additional Applications:

	 	OUI Project 16867: Influenza A haemagglutinin antigen Group
2 (H3)

 - site of limited variability

 
	 	 	 
	 	 	QUI Project 16870: Influenza
Group B haemagglutinin antigen - site of limited variability
	 	 	 
	 	 	QUI Project 16872: VLP delivery system for influenza vaccine

 

	PCT National Phase filing deadline:	 	25th February 2019
	 	 	 
	Inventor:	 	Craig Thompson and Sunetra Gupta
	 	 	 
	Territory (clause 3.1):	 	Worldwide
	 	 	 
	Field (clause 3.1):	 	All fields
	 	 	 
	Documents (clause 3.2):	 	The Applications.
	 	 	 
	Past Patent Costs (clause 6.1): 	 	£11,323.00
	 	 	 
	Signing Fee (clause 9.1): Royalty	 	$0
	 	 	 
	Rate (clause 9.2):	 	6%
	 	 	 
	Step-Down Royalty Rate (clause 9.3):	 	50% of Royalty Rate
	 	 	 
	Minimum Sum (clause 9.4	 	 

 

	Licence Year	 	(Annual) Minimum Sum
	Years 1- 3	 	[***]
	Year 4 - Year pre-Phase Ill	 	[***]
	Year of Phase Ill - Year of Launch	 	[***]
	Years Post Launch - Year Step down Royalty applies	 	[***]
	Once Step-Down Royalty applies	 	[***]

 

    17

     

    

 

Fee Income Royalty Rate (clause 9.5): 25%

 

Milestone and Milestone Fee (clause 9.6):

 

	Milestone	 	Milestone Fee
	Initiation of first Phase I study	 	[***]
	Init iation of fi rst Phase II study	 	[***]
	Initiation of Phase Ill/pivotal registration studies	 	[***]
	First submission of application for Regulatory Approval 
(BLA/NDA)	 	[***]
	Marketing authorisation in USA	 	[***]
	Marketing authorisation in any EU country	 	[***]
	Marketing authorisation in Japan	 	[***]
	First M arket ing authorisation in any ROW country	 	[***]
	First commercial sale in US	 	[***]
	First commercial sale in any EU country	 	[***]
	First commerc ial sale in Japan	 	[***]
	First commercial sale in any ROW country	 	[***]
	First year that Annual sales equal or exceed $500,000,000	 	[***]
	First year that Annual sales equal or exceed $1,000,000,000	 	[***]

 

RPI on date of this agreement (clause 9.8):289.2

 

Licensee’s Contact and Address (clause 14.6):

 

	Contact	Joe Hernandez
	Address	
    1013 Centre Rd,

    Suite 403-B New Castle Wilmington

    Delaware 19805 USA

	email	hernandez joe@y ahoo.com

 

    18

     

    

 

Schedule 3

 

DEVELOPMENT PLAN

 

Document entitled: “Process Development and CGMP Manufacturing
of Recombinant Influenza Conserved Regions for Vaccine Production” from Ology Bioservices dated 22nd May 2019.

 

    19

     

    

 

 

 

     

    	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

    

 

	TABLE OF CONTENTS	 	 
	1.0 PROJECT OVERVIEW	 	3
	2.0 TECHNICAL APPROACHAND PLAN	 	4
	TASK 1: TECHNICAL TRANSFER AND PROCESS ESTABLISHMENT	 	4
	TASK 2: ANALYTICAL ASSAY DEVELOPMENT	 	7
	TASK 3: CGMP MASTER AND WORKING CELL BANKING	 	8
	TASK 4: PROCESS SCALE-UP AND OPTIMIZATION	 	9
	TASK 5: ENGINEERING RUN AND STABILITY IBSTING	 	11
	TASK 6: CGMP RUN AND STABILITY IBSTING	 	13
	TASK 7: DRUG PRODUCT ENGINEERING AND CGMP DRUG PRODUCT	 	15
	TASK 8: REGULATORY SUPPORT FOR PRECLINICAL IND-ENABLING STIJDIES AND IND PREPARATION	 	16
	3.0 SCHEDULE AND WORK BREAKDOWN STRUCTURE	 	18
	4.0 PROJECT BUDGET & MILESTONE PAYMENT SCHEDULE	 	18
	APPENDIX A- GENERAL ASSUMPTIONS	 	19
	APPENDIX B - FACILITIES AND EQUIPMENT	 	20
	APPENDIX C - QUALITY SYSTEMS	 	26
	APPENDIX D - PROGRAM AND RISK MANAGEMENT	 	33
	APPENDIX E - RELEVANT COMPANY EXPERIENCE	 	42
	 	 	 
	LISTING OF TABLES	 	 
	Table 1. Task 1 Technical Assumptions	 	4
	Table 2. Task l Deliverables	 	7
	Table 3. Task 2 Technical Assumptions	 	7
	Table 4. In-Process and Drug Substance Release Testing	 	7
	Table 5. Task 2 Deliverables	 	8
	Table 6. Task 3 Technical Assumptions	 	8
	Table 7. Cell Bank Release Assays	 	8
	Table 8. Cell Bank Stability Assays	 	9
	Table 9. Task 3 Deliverables	 	9
	Table 10. Task 4 Technical Assumptions	 	9
	Table 11. RCB Release Assays	 	9
	Table 12. Equipment list for OS Manufacturing at the ADM Facility	 	10
	Table 13. Task 4 Deliverables	 	10
	Table 14. Task 5 Technical Assumptions	 	11
	Table 15. Drug Substance Stability	 	12
	Table 16. Task 5 Deliverables	 	12
	Table 17. Task 6 Technical Assumptions	 	13
	Table 18. Task 6 Deliverables	 	15
	Table 19. Task 7 Technical Assumptions	 	15
	Table 20. Drug Product Release Assay	 	15
	Table 21. Drug Product Stability	 	15
	Table 22. Task 7 Deliverables	 	16
	Table 23. Task 8 Technical Assumptions	 	16
	Table 24. Task 8 Deliverables	 	18
	Table 25. Project Schedule	 	18
	 	 	 
	LISTING OF FIGURES	 	 
	Figure 1. Upstream Fermentation Process	 	5
	Figure 2. Downstream Process Flow Diagram	 	6

 

    	Ology Bioservices, Inc.	Proprietary
	2

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

EXECUTIVE SUMMARY

Ology Bioservices, Inc. (Ology Bio) welcomes
the opportunity to perform Process Development and CGMP Manufacturing of Recombinant Influenza Conserved Regions for Vaccine
Production for Blue Water Vaccines, Inc. (Blue Water). Blue Water is currently developing a novel influenza vaccine based on four
conserved regions of the influenza virus. Each of these conserved regions encodes a unique 15-20 amino acid peptide sequence. Blue
Water has demonstrated the each of these peptides is highly immunogenic and conserved over many different strains of influenza.
These peptides are currently being combined into a single large polypeptide vaccine candidate and expressed in E coli. The present
scope of work includes the timely process development and manufacture of the novel influenza vaccine candidate suitable for
pre-clinical animal studies and Phase 1 clinical studies. The proposed schedule, assuming a start date of July 8, 2019, and material
pricing of the outlined work are provided in Sections 3.0 and 4.0, respectively. The estimated budget for the outlined work is
$4,325,012, including raw materials and supplies and an IND-enabling nonclinical study.

 

1.0 PROJECT OVERVIEW

 

1.1 Project Scope:

 

This proposal
consists of eight Tasks required to manufacture and release a CGMP lot of Drug Substance (DS) and Drug Product (DP) suitable for Clinical
Development and conduct preclinical IND-enabling studies and prepare the IND. Specific details of each task are provided in Section 2.0.
Ology Bio will work collaboratively with Blue Water and Ology Bio’s qualified subcontractors to provide a comprehensive program using
experienced scientists. To meet the requirements of this project, we have assembled a highly qualified and experienced team of Subject
Matter Experts (SMEs) with domain expertise in all disciplines required to successfully accomplish the scope of work.

 

Task 1: Technology Transfer and Process Establishment

Task 2: Analytical Assay Development

Task 3: CGMP Master Cell and Working Cell Banking

Task 4: Process Development and Scale-up

Task 5: Engineering Run and Stability Testing

Task 6: CGMP Run and Stability Testing

Task 7: Drug Product Engineering and CGMP Drug
Product

Task 8: Regulatory Support for Preclinical IND-Enabling
Studies and IND Preparation

 

1.2 Company Overview:

 

Ology
Bio is a privately held company founded in 1999 as an integrated biopharmaceutical company with a focus on product development and manufacturing.
Ology Bio has capabilities in analytical development and validation, process transfer, development and scale-up, formulation optimization,
CGMP manufacturing and regulatory services for development of biopharmaceutical products and medical devices through licensure. Ology
Bio has several proprietary platform technologies that can be used with all drug types, including but not limited to small molecules,
proteins, monoclonal antibodies and vaccines.

 

Ology
Bio has existing capabilities with internal expertise or specialized expertise of our contractors/teaming partners to successfully execute
each stage of the development program. The capabilities include established processes and procedures for Program Management, Technology
Transfer, Process Development, CGMP Formulation and Fill, Quality Control (QC), Quality Systems (QS), and Regulatory Chemistry, Manufacturing
and Controls (CMC) technical writing support. The ADM Facility provides the following features:

 

		●	Accommodation of Single-use Technologies (SUTs) to provide significant advantages in cost, operational
flexibility, and reliability

		●	Process Development Laboratories to accommodate small and pilot-scale development work and engineering
runs including capability for BSL-3 agents

		●	QC in-process testing and release capability

 

    	Ology Bioservices, Inc.	Proprietary
	3

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

		n	Agile,
                                            flexible manufacturing based on single-use, skid-mounted process equipment in both pilot
                                            plant and manufacturing core to facilitate the rapid changeover of process configurations
                                            for different platform technologies within production suites

		n	Four
                                            CGMP suites providing concurrent production capacity.

 

As
required to fulfil the scope of a project, Ology Bio will also engage the specialized services of our highly experienced and QA qualified
contractors for specific scope in the project (DP formulation and fill, outsourced testing, shipping).

 

2.0
TECHNICAL APPROACH AND PLAN

 

Task
1: Technology Transfer and Process Establishment

 

Table
l. Task 1 Technical Assumptions

 

 

Information
Transfer and Gap Assessment:

The
Information Transfer stage is critical for the success and timeliness of the project. Ology Bio requests that all pertinent documents
from Blue Water will be supplied within 5 days of contract signing to allow enough time for critical review by the Ology Bio team. A
kick-off meeting will be scheduled with review of the plans and timelines. After the project gap analysis is complete, a final schedule
and Gantt chart will be completed.

 

Receiving
Blue Water Documentation:

To
initiate the Technology Transfer, we will conduct a thorough review of all process and analytical documents provided by Blue Water. In
collaboration with Blue Water, we will create a Development Plan and governance process to meet the objectives of the project. Blue Water
will provide Ology Bio with all applicable standard operating procedures (SOPs), process procedures, process transfer protocols, analytical
plans, specifications and other knowledge to transfer analytical methods and the manufacturing process. Technology Transfer will include
the following preparation activities:

 

		n	Preparation
                                            of a Development Plan

		n	Preparation
                                            of documentation

		n	Equipment
                                            Identification

		n	Flow
                                            diagrams as appropriate

		n	Process
                                            step descriptions

		n	Risk
                                            Analysis and Mitigation Strategy

 

Transfer
of Product-Specific Materials from Blue Water and Procurement of Materials and Components:

Blue
Water will provide Research Cell Bank (RCB) vials, reagents and standards, and associated Certificates of Analysis (COAs), as required,
to Ology Bio within 5 days of contract signing in order to stay within the aggressive timeline for this program.

 

A
full list of raw materials will be developed and sent to Blue Water for approval. All consumables, expendables and raw materials will
be purchased using QA-approved vendors, properly inventoried and stored in the proper conditions. We may elect to purchase pre-prepared
media and certain buffers from agreed-upon suppliers to avoid any variability in these critical reagents in the process. We will identify
and qualify suppliers of production materials and any required excipients. The nature of this project will require that additional materials
identified in the Process Development Task to be communicated to Blue Water at a later date.

 

    	Ology Bioservices, Inc.	Proprietary
	4

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

Development
Plan and Reports:

Weekly
or biweekly presentations will be provided to Blue Water that summariz.es the performance of the process per plan. At the end of Task
1, a draft Development Plan will be written and reviewed/approved by both Ology Bio and Blue Water. The Development Reports will be written
after execution of Establishment Runs to contain details on each unit operation; trending of the data compared with any available historical
data (i.e., provided in Blue Water documents); analytical testing results; process deviations and impact assessment; our proposed process
changes, including assessment of impact and justifications for changes; and updated risk and gap assessment.

 

Process
Establishment:

Ology Bio will perform two
Process Establishment Runs to demonstrate the process for the Blue Water influenza vaccine candidate at laboratory scale (1 L shake flask)
and prepare a process transfer final report for approval by Blue Water. Ology Bio will use the existing RCBs from Blue Water to perform
these runs. Ology Bio proposes to remove the His-tag from the existing vaccine candidate in Task 4. Upstream and Downstream Process Flow
Diagrams for the production of the Blue Water influenza vaccine candidate are shown in Figure 1 and Figure 2.

 

Figure 1. Upstream Fermentation Process

 

 

 

    	Ology Bioservices, Inc.	Proprietary
	5

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

Figure 2. Downstream
Process Flow Diagram

 

 

 

Limited
testing will be performed on these Establishment runs. These will include SDS PAGE, protein concentration and HPLC analysis for purity.
We will also present a preliminary Bill of Materials (BOM) at the end of this task.

 

A
list of deliverables for Task 1 is shown in Table 2.

 

    	Ology Bioservices, Inc.	Proprietary
	6

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

Table
2. Task 1 Deliverables

 

 

Task
2: Analytical Assay Development

 

Table
3. Task 2 Technical Assumptions

 

 

A
complete list of analytical assays will be provided by Blue Water or agreed upon with Ology Bio. Specifications for each of the assays
will also be provided by Blue Water or agreed upon with Ology Bio. We propose to perform Technology Transfer feasibility assessments
on the QC assays outlined in Table 4 for in process (IP) testing and DS testing. Stability and DP testing are described in Tasks
6 and 7, respectively. Following the Technology Transfer feasibility assessment, QC scientists will revise method SOPs (as required)
and verify methods for testing. Upon completion of the verification studies, a comprehensive report, reviewed and approved by QA, will
be provided documenting the results of the verification, the suitability of the intended method, a description of test samples, a description
of experiments and a summary of data for each parameter tested, as well as relevant raw data obtained from these studies. These assays
will also be qualified as suitable for CGMP release and use in Phase 1 clinical trials. Testing will not be outsourced without the prior
written consent of Blue Water.

 

Table 4. In-Process and Drug Substance
Release Testing

 

  

    	Ology Bioservices, Inc.	Proprietary
	7

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

 

	1	Assay
will be Tech Transferred to Ology Bio

 

A list of deliverables
for Task 2 is shown in Table 5.

 

Table
5. Task 2 Deliverables

 

 

Task
3: CGMP Master and Working Cell Banking

 

Table
6. Task 3 Technical Assumptions

 

In
compliance with CGMP Regulations, Ology Bio will produce a minimum of 300 vials of a Master Cell Bank (MCB) per QA-approved batch production
records using the RCBs generated by Ology Bio as part of Task 4. The new Blue Horizon vaccine candidate will not contain a His-tag. These
RCBs will be utilized for the production of the CGMP MCBs. The new MCB will undergo characterization and release testing based on an
analytical control strategy outlined in Table 7. Ology Bio proposes to generate CGMP Working Cell Banks (WCBs) from the MCBs and
characterize them.

 

Table
7. Cell Bank Release Assays

 

 

An
annual stability program will also be initiated and will be continued for up to three years for both MCB and WCB. For budgeting purposes,
testing will only be conducted for 12 months, but cells will remain on stability for future testing. The stability testing is provided
in Table 8.

 

    	Ology Bioservices, Inc.	Proprietary
	8

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

Table
8. Cell Bank Stability  Assays

 

 

Table
9. Task 3 Deliverables

  

Task
4: Process Scale-up and Optimization 

 

Table
10. Task 4  Technical Assumptions

 

Based
on the results observed from the Process Establishment runs, we will redesign the expression system to remove the His-tag from the
coding region of the vaccine candidate. The new plasmid will be evaluated using two different E coli expression systems: one based
on IPTG induction, the other based on phosphate depletion (PhoA). The expression system that yields the highest soluble titer will
be selected for further development. We will initially generate RCBs. We will identify three individual colonies, and each of the
colonies will be analyzed for protein production at the 1-3 mL scale. Two colonies will be scaled up and used to generate SO vials
of RCB. These RCBs will then be utilized for production of the CGMP MCBs and WCBs as described in Task 3. Each RCB will be
characterized as per Table 11.

 

Table
11. RCB Release Assays

 

 

These
RCBs will be used for the initial process development studies. The process development will focus on both the upstream and
downstream processing of the vaccine candidate. Small-scale upstream production runs ( 1 L scale) will be used to generate materials
for the downstream processing. Ology Bio proposes to use their rapid chromatography screening protocols to identify and optimize the
chromatographic procedures required for the purification of the Blue Water vaccine candidate. Ology Bio proposes to scale-up the
manufacturing process to the 120 L scale to generate the required 1-2 grams required for this project. This will include five 3 L
production runs to identify the optimum upstream parameters for maximum production of the vaccine candidate.

 

    	Ology Bioservices, Inc.	Proprietary
	9

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

In
parallel, the downstream processing will be optimized as described above and then scaled to the 3 L scale. Ology Bio then proposes to
perform two scale-up runs at the 120 L scale using the 150 L stainless steel fermenter, the proposed manufacturing production scale.
These runs will be analyzed using the in-process and release tests as described in Task 2. Success criteria for these runs will be agreed
upon by Blue Water and Ology Bio prior to initiation of these runs. The sampling plan for these runs will also be agreed upon prior to
initiation of the runs. Draft batch records and a final sampling plan will be prepared for use in the Engineering runs (Task 5).

 

Equipment
required to support all the required tasks for the program are in-place and have been previously qualified at the ADM Facility, as listed
in Table 12. Should additional equipment be required, qualification will be performed per standard operating procedures prior
to CGMP manufacturing.

 

Table
12. Equipment list for DS Manufacturing at the ADM Facility

 

Deliverables
for this task are provided in Table 13.

 

Table
13. Task 4 Deliverables

 

 

    	Ology Bioservices, Inc.	Proprietary
	10

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

 

Task
5: Engineering Run and Stability Testing

 

Table
14. Task 5 Technical Assumptions

 

We
will perform one Engineering run at full scale of 120 L. The in-process and release testing plan for this run will be agreed upon by
Blue Water and Ology Bio. The Engineering run will be executed at the 120 L production scale by manufacturing staff in the CGMP manufacturing
core at the Facility. The Engineering run will be performed using draft Master Batch Records and QA-released raw materials and components.
The batch records will be redlined during the Engineering run, and any changes will be incorporated into the Master Batch Records prior
to approval for CGMP manufacturing. The in-process and release assays are described in Task 3, Table 4.

 

The
material generated from this lot will be indicative of the COMP-manufactured material. The materials from this lot will be made available
to Blue Water for additional studies. In addition, materials from this lot will be used to generate Reference Standard materials. ACOA
and Material Safety Data Sheet (MSDS) will be prepared at this stage. A completed BOM will be submitted as part of this Stage. The non-CGMP
OS material will be placed on stability studies.

 

Stability
Testing:

Stability testing
of non-CGMP Engineering DS will be conducted in accordance with current U.S. FDA Code ofFederal Regulations (CFR) and International Conference
on Harmonization (ICH) guidelines, including:

 

		n	21
                                            CFR Parts 210 and 211 (CGMPs)

		n	21
                                            CFR Part 312 (IND Application)

		n	ICH
                                            Q1 A(R2) Guideline: “Stability Testing ofNew Drug Substances and Products,” February
                                            2003

		n	ICH
                                            QlC Guideline: “Stability Testing of New Dosage Forms,” November 1996

		n	ICH
                                            QSC Guideline: “Stability Testing of Biotechnological/Biological Products,” November
                                            1995

 

The
stability evaluation will support the following:

		n	Use
                                            of the investigational product throughout nonclinical studies and clinical trials

		n	Mitigation
                                            of shipping and storage temperature excursion impact on the investigational product

		n	Stability
                                            of the product during handling (clinical sites, emergency-use scenarios)

		n	Selection
                                            of lot release and stability-indicating analytical test methods

		n	Expiration
                                            or retest dates for OS

		n	Product
                                            conformity to stability specifications throughout the clinical trial

 

The
proposed stability study for non-CGMP (as well as CGMP) OS lots is provided in Table 15. Stability testing will be conducted per
approved protocols and reported annually.

 

    	Ology Bioservices, Inc.	Proprietary
	11

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

Table
15. Drug Substance Stability

 

 

Reference
Standard:

Providing
high-quality, documented and qualified Reference Standards is critical to every batch released, and characterization can be an arduous
process. In accordance with our QS, Reference Standards are produced and qualified prior to use in lot release, characterization or stability
testing. The objective of this program is to provide complete documentation of the establishment and trending of product Reference Standards.
Another goal of the program is to assess the suitability and availability of Reference Standards and critical reagents to meet ICH and
FDA guidelines appropriate for the product lifecycle stage for which the materials will be used. This program results in complete documentation
of these Reference Standards by providing:

 

		n	Manufacture
                                            according to approved batch record or protocol

		n	Qualification
                                            according to approved qualification protocol

		n	Lot
                                            release testing according to approved technical specification

		n	Generation
                                            of a COA detailing the lot release testing results

		n	Controlled
                                            storage conditions and inventory

		n	Stability
                                            testing

		n	Continual
                                            data trending and evaluation of suitability in new/revised analytical methods and/or with
                                            changes to manufacturing process operations

 

For
the Blue Water program, interim DS Reference Standards will be established in accordance with an approved protocol from the DS
Engineering lot(s). To reiterate the approach to DS Reference Standard, a minimum of 1,000 vials of Engineering DS will be aliquoted
and qualified as the DS Reference Standard. The filled Engineering DP generated in Task 7will be labelled and qualified as the DP
Reference Standard. AQA-reviewed and approved Qualification Report will be provided that documents suitability of the DS and DP
Reference Standards in the intended methods. These interim DS and DP Reference Standards are to be used for Phase 1/2 product lot
release and stability testing.

 

A
list of deliverables for Task 5 is shown in Table 16.

 

Table
16. Task 5 Deliverables

 

 

    	Ology Bioservices, Inc.	Proprietary
	12

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

Task
6: CGMP Run and Stability Testing

 

Table 17. Task 6 Technical Assumptions

 

Table 17. Task 6 Technical Assumptions

 

Blue
Water and Ology Bio will agree on the analytical and IP testing plan for the routine production of the Blue Water vaccine candidate,
which we will implement. Following completion of the scalability studies, a Technology Transfer Protocol will be generated. This report
will describe the process development and define the critical process parameters and established ranges. The report will summarize lot
testing and establish a sampling and testing plan to be used during COMP manufacturing. A BOM listing all required raw materials and
components will be included. From this BOM, specifications will be created for each material, as well as for IP intermediates where required.
Batch records will be finalized and approved by QA for use in the CGMP manufacturing campaign. Any changes identified during the execution
of the DP Engineering run (Task 7) will be incorporated into the final CGMP batch records prior to execution.

 

We
will perform one COMP manufacturing campaign in accordance with:

 

		n	21
                                            CFR Parts 210 and 211 (CGMP)

		n	21
                                            CFR Part 312 (IND Application)

		n	21
                                            CFR Parts 600 and 610 (Biological Products)

		n	21
                                            CFR Part 11 (Electronic Records and Signatures)

 

To
lead to a successful campaign, we will use manufacturing readiness reviews to ensure that all activities are completed prior to the start
of manufacturing. We perform Area Clearance and Product Changeover according to internal SOP-09-00054. Trained Operations personnel will
clear manufacturing areas after manufacturing campaigns following work instruction WI-09-00004. Areas are cleaned according to SOP-09-00006,
including chlorine dioxide decontamination when appropriate. Activities are documented on forms and manufacturing areas are released
for use after QA review of these activities.

 

Our
QA takes responsibility for assuring the quality and integrity of products and all data generated in compliance with the FDA GLPs and
CGMPs. QA provides review of manufacturing and testing operations as well as approval of specifications, Master Batch Records, procedures,
contract manufacturers, system and equipment changes, and intermediate and final product release. Deviations and investigations are integrated
in a corrective action system. QA review and approval activities will be carried out in support of CGMP production campaigns on all the
following activities:

 

		n	Documentation:

		o	Raw
                                            Material Specifications

		o	Manufacturing
                                            Master and Executed Batch Records

		o	Equipment
                                            Operation and Maintenance SOPs

		o	Analytical
                                            Method SOPs

		o	Cleaning
                                            and Disinfection SOPs

		o	Harvest
                                            and Final Product Specification

 

		n	Manufacturing
                                            Cleanroom Preparation:

 

		o	Cleaning
                                            of Laboratory during Manufacturing

		o	Area
                                            Clearance and Product Changeover

		o	QA Audits

		o	Cleaning
                                            Validation Risk Assessment/Protocol, if applicable

 

		n	Reference
                                            Standard:

 

		o	Certification
                                            of Reference Standard

 

    	Ology Bioservices, Inc.	Proprietary
	13

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

		n	Raw
                                            Materials:

 

		o	Vendor Qualification

		o	Ordering of
                                            Raw Materials and Supplies

		o	Sampling of
                                            Raw Materials

		o	QC Testing
                                            of Raw Materials and Data Review

		o	QA Audit of
                                            Testing Data and Raw Material COAs

		o	QA Release
                                            of Raw Materials and Inventory Tracking

 

		n	CGMP
                                            Manufacturing:

 

		o	Manufacturing
                                            of DS

 

		n	Product
                                            Testing:

 

		o	QC
                                            Review of Testing Data

		o	QA Review
                                            of Testing Data and Preparation of COAs

		o	QA Release
                                            of DS Lot(s)

		n	Packaging
                                            and Shipping:

 

		o	Packaging
                                            and Shipping of DS

		n	Project
                                            Audit and Final Report

 

Documentation:

We
have a validated electronic Quality Management System, MasterControl, to automate and integrate processes for meeting quality standards
and complying with regulatory requirements. Master Control manages documents, training and risk; processes and audits; and facility and
equipment calibration and maintenance program. Documentation in MasterControl includes, but is not limited to, raw material specifications,
product specifications, MPR, equipment operation SOPs, and analytical method SOPs and protocols.

 

CGMP
manufacturing will be performed in compliance with CGMP regulations, including approved Master Batch Records, CGMP cell banks, active
environmental monitoring and QA release of all raw materials and consumables. Raw materials will be purchased using QA-approved material
specifications from QA-approved suppliers in accordance with our Supplier Selection, Assessment and Approval procedures (SOP-20-00018).
CGMP runs will be performed in the manufacturing core using the same equipment, facilities and personnel as utilized for the Engineering
Run.

 

Production:

Trained
manufacturing personnel will execute one CGMP production lot in accordance with QA-approved production records and SOPs. The CGMP
runs will be performed in the manufacturing core using the same equipment, facilities and personnel as utilized for the Engineering
run. The manufacturing core features ISO 8 in-operation (Grade C) processing rooms for all closed system operations. All open
manipulations will occur within the ISO 5 area (Grade A BSC) located within an ISO 7 in-operation (Grade B) suite adjacent to the
main processing room. Samples will be taken throughout the manufacturing process according to the batch record and product
specifications. The process will be executed aseptically from start to finish, as demonstrated in the process simulation as part of
Task 7. Bulk DS will be stored at ≤ -70°C fill/finish at Ology Bio.

 

The
CGMP material will be tested according to the OS specifications and tests previously defined. QC conducts in-process and lot release
testing per SOPs and sampling plans. QA will provide the final review of batch records, environmental monitoring and analytical
results. QA will also provide release of CGMP OS via a COA, ensuring that the DS product lot meets all technical specifications and
is acceptable for use in GLP, nonclinical studies and Phase l clinical studies.

 

Ology
Bio will perform limited stability testing as outlined in Task 5 and will provide samples as defined. A list of deliverables for Task
6 is shown in Table 18.

 

    	Ology Bioservices, Inc.	Proprietary
	14

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

Table
18. Task 6 Deliverables

 

 

Task
7: Drug Product Engineering and CGMP Drug Product

 

Table
19. Task 7 Technical Assumptions

 

After
completing the DS Engineering run, we will execute an Engineering run of the DP filling process using the final container and closure
method agreed upon with Blue Water (anticipated to be a 2 mL vial). The final formulation will include an adjuvant provided by Blue Water.
DP vials will be tested according to developed release criteria (Table 20) and placed on limited stability studies (Table 21).

 

Table 20. Drug Product Release
Assay

 

 

Table
21. Drug Product Stability

 

 

    	Ology Bioservices, Inc.	Proprietary
	15

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

 

 

In
accordance with FDA Guidance for Industry, “Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing
Practice,” Sept 2004, aseptic formulation and fill validation (media fill validation) will be conducted using a maximum
of2,000 vials per lot in a mutually approved container/closure system (vial, stopper, seal). Three consecutive successful media fill
Validation Runs will be performed using TBS to simulate the formulated DP according to an approved media fill validation batch
record. In addition, appropriate interventions (extended processing times, simulation of spillage and clean-up of spillage, changing
out of the fill needle) will be incorporated into the validation activities.

 

Phase
1 DP formulation and liquid product fill operations will be conducted at Ology Bio. Using QA-approved production documentation, the DS
lot will be formulated to achieve the final concentration of the to-be determined titer in the selected final formulation (determined
by Blue Water). Formulated product will be filled into the mutually approved container/closures within an aseptic area. A maximum of
2,000 vials per DP lot will be targeted for filling. QC will conduct lot release testing as summarized in Table 20 per batch records
and sampling plans. QA will provide the final review and release, ensuring that the DP lots meet all technical specifications and are
acceptable for use in GLP nonclinical studies and clinical studies. Stability testing of CGMP DP lots is described in Table 21.

 

A
list of deliverables for Task 7 is shown in Table 22.

 

Table
22. Task 7 Deliverables

 

Task
8: Regulatory Support for Preclinical IND-Enabling Studies and IND Preparation

 

Table
23. Task 8 Technical Assumptions

 

 

    	Ology Bioservices, Inc.	Proprietary
	16

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

Subtask
8.1: Pre-Clinical Tox Study

Ology
Bio will support Blue Water in the development of a nonclinical safety plan to support IND filing. Based on Ology Bio Regulatory experience,
CBER/FDA expects high-quality of material for the IND-enabling toxicity studies that is either CGMP material or comparable to CGMP material.
To reduce risk, the schedule linked this study to the CGMP lot. Blue Water can consider risks as it reviews the nonclinical safety plan.

 

Ology
Bio’s Nonclinical SME will work with the subcontractor, IITRI to develop a protocol for an IND-enabling study based on feedback received
from the FDA during the Pre-IND meeting (Subtask 8.2). Ology Bio will oversee the performance and of a GLP-Compliant Repeat Dose Toxicity
Study of the Influenza Vaccine Candidate in Rabbits. The objective of the study will be to determine the immunogenicity, target organ
toxicity, and reversibility of the influenza vaccine in rabbits following a repeat dosing regimen to support a Phase 1 clinical study.

 

Subtask
8.2: Pre-IND Meeting Support

Ology
Bio will support a Type B Pre-IND Meeting to ensure successful entry into first-in-man studies. Effective communication with the FDA
during the pre-IND stage of product development fosters a strong working relationship and is important for clearance of the IND. Ology
Bio Regulatory Affairs (RA) team will respond to information requests received prior to the meeting, support meeting participation and
prepare meeting minutes. Our RA team will be engaged in practice sessions to develop responses to potential FDA questions and address
concerns to avoid delays in product development. Our RA team tracks risks associated with entry into clinical development and ensures
that the meeting reduces risk by proper preparation.

 

The
Pre-IND meeting will include briefing materials describing the Phase 1 Protocol Synopsis; nonclinical toxicity· plan; CMC technical
information including cell banking and detailed manufacturing process descriptions; release; and stability information. Specific questions
will focus on acceptability of the information to be provided in the IND.

 

Subtask
8.3: Regulatory Technical Writing

To
support Blue Water in developing their IND application, our RA experts will prepare CMC sections for Blue Water’s vaccine. Ology
Bio will provide Tier I, Tier 2 and Tier 3 regulatory support, which includes technical review of strategic documents (i.e., specifications,
change controls, protocols, risk assessments and technical reports) and CMC technical writing. Ology Bio will author the DS CMC information
(Quality Modules 3.2.S, 3.2.P and 3.2A) in ICH Common Technical Document (CTD) format, delivered as Microsoft Word documents. CMC technical
writing will be limited to manufacturing and testing activities managed by Ology Bio, and placeholders will be included for Blue Water-managed
activities. In addition, Ology Bio will support development of Modules 4 and 5 with deliverables provided in Word. Electronic Publishing
costs are not included in this proposal.

 

The
Ology Bio RA team is responsible for managing, writing, completing or editing all technical writing assignments; obtaining drop-in documents
from the SMEs; assembling all documents and forms into a submission package; and uploading the submission for review and approval. Our
RA team works with SMEs as needed to complete editing and addressing reviewers’ comments. RA is responsible for working with QA staff
to ensure that all information/data has been reviewed for accuracy prior to Client review of documents. For this effort, Ology Bio assumes
that clinical SMEs will be provided by the Sponsor to support protocol development and review.

 

Our
RA team uses eCTD Word templates that provide authors with the ability to create documents that adhere to a single standard for consistency
to the FDA and to our clients. Scientifically sound and accurate CMC writing to support CTD Module 3 development is critical to the success
of the CMC communications with Regulatory authorities. Cost and regulatory operations support for electronic publishing and filing of
the IND is not included.

 

    	Ology Bioservices, Inc.	Proprietary
	17

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

Table
24. Task 8 Deliverables

 

 

3.0
SCHEDULE AND WORK BREAKDOWN STRUCTURE

 

The project
schedule is presented in Table 25. The proposed start date for this project is July 8, 2019; this start date is subject to change
based on the date this proposal is accepted and signed and availability of the facility.

 

Table
25. Project Schedule

 

4.0 PROJECT
BUDGET

 

 

	1	Task
                                            prices are based on estimated time.

	2	Material
                                            costs are estimated for budgeting purposes and include a 15% material handling fee.

	3	GLP
                                            compliant IND-enabling tox study performed by Ology Bio subcontractor

 

    	Ology Bioservices, Inc.	Proprietary
	18

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

APPENDIX
A- GENERAL ASSUMPTIONS

 

The schedules, estimates and costs contained
within this proposal are based on the Listing of Technical Assumptions and the following General Assumptions. If any of these assumptions
are incorrect, Ology Bio reserves the right to re-estimate both the schedule and the cost for this proposal.

		1	Ology
                                            Bio technological proposal is a suggested pathway based on the information provided. Additional
                                            and/or replacement of the techniques as result of new and/or more (or less) detailed information
                                            from Blue Water may affect the content and pricing of this proposal.

		2.	Blue
                                            Water will make available the appropriate SMEs and stakeholders as needed.

		3.	Blue
                                            Water will provide sufficient materials required to begin assay development.

		4.	Ology
                                            Bio assumes that active and responsive participation and availability by Blue Water SMEs,
                                            stakeholders, etc., will exist throughout the length of this project in support of project
                                            scope, schedule, and team.

		5.	Access
                                            to development/practice/test documents will be available at contract start.

		6.	Full
                                            cooperation and conditions obtained from any/all applicable external third parties (manufacturers,
                                            service providers, leasers, etc.) required by the scope of this project will be acceptable
                                            to Ology Bio. Unfavorable conditions (terms, costs, etc.) will require that alternative solutions
                                            be found.

		7.	Timelines
                                            are bound to the specific period outlined in this proposal. As such, the appropriate space
                                            and resources will be allocated to this project during that timeframe. In the event of delays
                                            resulting in activity or inactivity of Blue Water, additional charges and an extension of
                                            the timeline may become necessary.

		8.	Ology
                                            Bio will work in good faith based on agreed upon terms and in cooperation of the needs of
                                            Blue Water. All activities associated with this project remains at the discretion of Ology
                                            Bio.

		9.	A
                                            mutually agreed-upon Decision Log will be used to make and record non-substantial changes/modifications
                                            to the contract without the need for a complete formal amendment. The Decision Log will be
                                            referenced as incorporated into the contract.

		10.	This
                                            estimate is valid for 60 days and until this proposal is signed as a contract document and
                                            agreed upon by both parties. Ology Bio reserves the right to adjust pricing based on new
                                            data, market cost fluctuations, and additional work requested by Blue Water prior to execution
                                            of the contract.

 

    	Ology Bioservices, Inc.	Proprietary
	19

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

APPENDIX
B- FACILITIES AND EQUIPMENT

 

Ology
Bio operates a 180,000 ft2 multi-purpose, multi-product biologics and vaccine facility in Alachua, FL. Ology Bio provides
capabilities for analytical testing, scale-up and development, CGMP cell and viral banking and storage, and CGMP manufacturing with the
ability to handle pathogens at biosafety levels up to BSL-3. The main functions of the DoD Advanced Development and Manufacturing (ADM)
Facility include testing, developing and CGMP manufacturing of biologics including:

 

		n	Vaccine
                                            products (bacteria, viruses and virus-like particles)

		n	Monoclonal
                                            antibodies from cell culture

		n	Recombinant
                                            proteins from various expression platforms (E. coli, yeast, insect, and mammalian
                                            cells)

		n	Master
                                            and Working Cell and Viral Banks

		n	Concurrent
                                            manufacturing of multiple CGMP bulk biologics via four independent production rooms

 

The
ADM Facility provides the following features:

 

		n	Accommodation
                                            of SUTs to provide significant advantages in cost, operational flexibility, and reliability

		n	Availability
                                            of traditional stainless-steel equipment capable of clean in place and sterilize in place
                                            for fermentation and cell disruption

		n	Process
                                            Development Laboratories to accommodate small and pilot scale development work and engineering
                                            runs including capability for BSL-3 agents

		n	QC
                                            in-process testing and release capability

		n	Agile,
                                            flexible manufacturing based on single-use, skid-mounted process equipment in both pilot
                                            plant and manufacturing core to facilitate the rapid changeover of process configurations
                                            for different platform technologies within production suites

		n	The
                                            ability to accommodate up to four x 2,000 L bioreactors

		n	BSL-3
                                            compliant facility design to allow development and manufacture up to BSL-3 conditions

 

Key
areas of the ADM Facility depicted in Figure B-1 include:

 

Figure
B-1. Key Areas of the ADM Facility

 

 

 

    	Ology Bioservices, Inc.	Proprietary
	20

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

Area
A:

 

		n	General
                                            Office

		n	Administration
                                            Spaces

 

Area
B:

 

		n	CGMP
QC Laboratories including:

 

	 	o	Microbiology
		o	Cell assay

		o	Analytical
                                            Chemistry

		o	Sample Management
                                            and Stability

		o	BSL-3

		n	Development
                                            laboratories including:

		o	Vector Development

		o	BSL-3

		o	Pilot Plant

		n	CGMP
                                            Viral Banking suite

		n	Cell
                                            Banking suite

 

Area
C:

 

		n	CGMP
                                            Mfg. Core consisting of two CGMP, BSL-3 compliant manufacturing suites each consisting of:

		o	Upstream
                                            Processing (USP) room

		o	Downstream
                                            Processing (DSP) room

 

    	Ology Bioservices, Inc.	Proprietary
	21

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

		o	Media
                                            and Buffer Preparation (MBP) room

		o	Weigh
                                            and dispense areas

		o	Washing
                                            and sterilizing areas to support CGMP manufacturing

		o	Shell
                                            Expansion Space for future build-out

 

Area
D:

 

		n	Central
                                            Utility Plant

 

Area
E:

 

		n	CGMP
                                            Warehouse

 

Upstream
and Downstream Capabilities:

 

The
ADM Facility can rapidly manufacture bulk product using a variety of biopharmaceutical processes and manufacturing technologies and platforms.
The manufacturing core consists of two production suites that can be equipped, as needed, to accommodate various campaigns. In the typical
set-up, each suite comprises one USP room and one DSP room. In addition, each suite is supported by a MBP room located between the USP
and DSP rooms. However, to maintain flexibility, the four processing rooms can operate similarly, with possible assignment of the suites
to either upstream or downstream operations as required to support necessary adjacencies for flexible manufacturing. The USP and DSP
rooms are operated on a campaign basis for CGMP manufacturing with only one product in a room at a time.

 

The
suites are designed as open floor with the ability to operate multiple pieces of process equipment simultaneously using primarily closed
SUT to reduce or eliminate possibilities of cross contamination. Furthermore, most of the process equipment, including MBP systems are
portable and thus removable and reconfigurable based on manufacturing and facility requirements. No process equipment is permanently
fixed within the core manufacturing area.

 

All
production rooms are BSL-3 capable and designed to promote unidirectional flow of personnel and materials. All BSL-3 waste materials
are appropriately decontaminated in dedicated decontamination autoclaves located within each USP and DSP room, following established
Standard Operating Procedures (SOPs).

 

Manufacturing
Core Layout:

 

The
CGMP manufacturing core consists of a series of open hall cleanrooms designed and constructed for biopharmaceutical manufacturing of
bulk biologics. These cleanrooms are logically arranged with the proper adjacencies to allow predominately unidirectional flow of personnel,
product, materials and wastes. Each processing suite of the CGMP manufacturing core consists of the following functional areas:

 

BSL-3
Commissioned USP Room with:

 

		n	ISO
                                            Class 8 (ISO 8) Clean Staging Room

		n	ISO
                                            8 Gown-in Personnel Airlock (PAL) and Material Airlock (MAL)

		n	ISO
                                            8 Processing Room equipped with decontamination autoclave

		n	ISO
                                            Class 7 (ISO 7) Gown-in Room

		n	ISO
                                            7 Inoculum Preparation Room (with ISO Class 5 BSC)

		n	ISO
                                            8 Degown PAL and MAL

		n	ISO
                                            8 Exit Staging Room with shower out capabilities.

 

BSL-3
Commissioned DSP Room with:

 

		n	ISO
                                            8 Clean Staging Room

		n	ISO
                                            8 Gown-in PAL and MAL

		n	ISO
                                            8 Processing Room equipped with decontamination autoclave

		n	ISO
                                            7 Gown-in Room

		n	ISO
                                            7 Bulk Filling Room (with ISO 5 BSC)

 

    	Ology Bioservices, Inc.	Proprietary
	22

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

		n	ISO
                                            8 Degown PAL and MAL

		n	ISO
                                            8 Exit Staging Room with shower out capabilities.

 

MBP
ISO 8 Room with:

 

		n	entry
                                            and exit airlocks

 

Process
Support Rooms with:

 

		n	ISO
                                            8 Rooms for glassware wash and sterilization capabilities

 

This
design concept, with the MBP room between the USP and the DSP rooms is integral to the success of agile, flexible operations with SUS.
The adjacency provides media/buffers/reagents to both rooms through liquid transfer ports. This greatly reduces traffic into and out
of the processing areas, and greatly cuts down on buffer/media vessel congestion in the processing areas. Smaller quantities of media
and buffer components can be transported manually via carts to the USP or DSP suites via the clean staging room and supply corridor,
as needed, or make use of single-use Sartorius Biosafe rapid transfer ports, which accommodate aseptic tubing transfers. For space planning
purposes, these suites have bench space for in-process analysis instrumentation, space for a portable CIP skid, consumables and tools
carts, tubing welders and sealers, integrity testers, automation panels, biowaste kill system, and utility drops within the room.

 

TheADM
Facility has a dedicated CGMP Cell Banking area for the creation of MCB and WCB and adedicated CGMP Viral Banking area for creation
of viral stocks and infections agents. These ISO 7 cleanrooms are used on a campaign basis and may be used for other manufacturing
activities as required. All open manipulations occur in an ISO 5 biosafety cabinet within the room. The Cell Banking and Viral
Banking laboratories are located within the development area of the ADM Facility, in a monitored, secured and controlled
environment, with access to the room through controlled airlocks.

 

Table
B-1. ADM Facility Capabilities and Equipment

 

 

    	Ology Bioservices, Inc.	Proprietary
	23

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

 

 

The
ADM Facility is designed to be a multi-product facility. The four processing rooms are capable of ClO2 decontamination, including
associated inlet and outlet airlocks and the HVAC air-handling systems, each of which is individually zoned. Product changeover will
be performed per SOP and validated decontamination procedures and will feature final room clearance by QA. Equipment is designed to
be predominately single-use and will be capable of decontamination within the processing rooms prior to a new campaign. In addition
to product changeover activities, the manufacturing core and support areas will be sanitized according to daily, weekly and monthly
schedules using qualified and rotated cleaning agents and disinfectants. An environmental monitoring program is in place to monitor
the effectiveness of the cleaning procedures and ensure continued performance of the cleaning program. CGMP manufacturing activities
are also supported by the Logistics and Manufacturing Technical Services (MTS} Departments. The ADM Facility features a warehouse
consisting of 22,375 f22 of controlled room temperature space. The warehouse is also equipped with a cold room storage area
(2-8° C), -20° C and -80° C freezers.

 

Water for
Injection System:

The
Water for Injection (WFI) System includes equipment for generation, storage and distribution. The WFI generation system receives USP
Purified Water from the central utilities plant and has been designed to condition incoming USP Purified Water into WFI using a
multi-effect distillation process. The distilled WFI flows into a 9,000 L storage tank which provides capacity to manage peak demand
and maximize generation equipment utilization. The WFI still output is designed for 300 gallons per hour (GPH). Combined with the
9,000 L storage tank the total generation capacity for WFI is approximately 33,500 L per day, which exceeds any envisioned surge
scenario. To ensure microbial integrity, the contents of the WFI system is maintained hot ( ≥60°C to 85°C) by heating the
water as it returns from the loop before returning to the storage tank. The WFI distribution loop is a continuous circuit that
begins on the mezzanine and is distributed to the WFI Points of Use (POUs) in the preliminary sequence. There are 11 POUs for the
Facility, IO in the CGMP core, including one to the manufacturing parts washer, and one in the Pilot Plant. Users requiring ambient
WFI utilize a POU heat exchanger.

 

The
WFI Loop instrumentation includes:

 

		n	Conductivity on the loop supply and return,

		n	Total Organic Carbon on the loop return,

		n	Temperature at the outlet of the loop-return heat exchanger, and

		n	Pressure on the loop return.

 

    	Ology Bioservices, Inc.	Proprietary
	24

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

Clean Steam:

The
clean steam system consists of a high purity clean steam generator and 316 L SS tubing distributed throughout the manufacturing core
for sterilization and/or sanitization of equipment, parts and systems. The clean steam, when condensed, meets the requirements of USP
for Purified Water. Additionally, the steam quality has been evaluated for superheating, dryness and non-condensable gasses per EN285.

 

Pharmaceutical
Air and Clean Gases:

Carbon
Dioxide, Oxygen, Clean Compressed Air, Nitrogen, and Instrument Air are distributed throughout the CGMP core for equipment use. Each
processing space contains utility panels enabling connection of equipment to these gases. A second system is provided to supply the Cell
and Viral Banking laboratories, Pilot Plant, and QC and Development laboratories.

 

Validation
Program:

All
direct impact utilities, process equipment and QC/Manufacturing laboratory instruments require qualification before use. MTS is responsible
for tracking validation status, developing validation protocols, select protocol execution and writing validation summary reports. Third-party
vendors are also used to supplement Ology Bio validation resources. QA Engineering provides oversight of the Ology Bio validation program
and documentation. System and equipment requalification requirements are based on industry standards, regulatory requirements and periodic
system quality evaluations. In addition, requalification may be performed if required by the Ology Bio change control process. Periodic
certification of environmental systems and occasional recertification (after repair or relocation of affected equipment) is managed under
the routine maintenance and calibration programs discussed above.

 

Change
Control:

Ology
Bio follows a systematic approach to manage proposed changes to products, systems, and processes. Changes are evaluated for their potential
impact to product or system quality as well as impact to other systems and products. The need for re-verification and/or re-validation
is determined and the associated data reviewed prior to implementation of the change. Changes to critical facilities, utilities systems
and equipment are managed and documented using the MasterControl eQMS system following established Change Management Program and Change
Control Process SOPs. Indirect and no-impact system changes and equipment changes prior to qualifications are documented as per the Engineering
Change Management Procedure SOP.

 

    	Ology Bioservices, Inc.	Proprietary
	25

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

APPENDIX
C - QUALITY SYSTEMS

 

Quality
Systems Overview:

 

Ology
Bio’s QS ensures compliance with CGMP Regulations, 21 CFR Part 211 and ICH Guidance for Good Manufacturing Practices for Active Pharmaceutical
Ingredients -ICH Q7 and Biologics Regulations, 21 CFR Part 600. Ology Bio’s Quality Management System (QMS) is ISO 9001 certified for
the development, manufacture and distribution of biologics, pharmaceuticals and medical devices. Ology Bio QMS is comprehensive and provides
processes and procedures necessary to perform all core QMS elements including:

 

		n	Management
                                            review

		n	Document
                                            management and control

		n	Deviations

		n	(CAPA)

		n	Change
                                            control

		n	Supplier
                                            selection and management

		n	Quality
                                            agreements

		n	Quality
                                            audits

		n	Employee
                                            training

		n	Calibration

		n	Customer
                                            complaint handling

 

The
ADM Facility uses a combination of 21 CFR Part 11 compliant eQMS systems to manage the QMS processes. The selection of the eQMS systems
was based on the degree to which each system met our performance expectations for each function, cost and the ease of implementation.
The Quality Assurance (QA) Department reports to the Vice President of QA and is organized into functional areas providing comprehensive
oversight of all QMS elements as listed below:

 

Table
C-1. QA Core Functions

 

 

    	Ology Bioservices, Inc.	Proprietary
	26

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

 

Quality
Agreement:

 

Ology
Bio will work with Blue Water to establish a mutually approved Quality Agreement that defines the quality requirements and responsibilities
of each organization.

 

Quality
Audit:

 

Ology
Bio will support Blue Water quality audits of Ology Bio’s systems and procedures, insofar as they relate to the service and control of
Blue Water product. These audits may be performed on a periodic basis, not more than once per year, at times mutually agreed upon by
Ology Bio and Blue Water. Ology Bio will provide Blue Water with monthly follow-ups on the status of audit observation commitments found
in Blue Water annual audit or regulatory inspection, as they apply to Blue Water product.

 

Quality
Software:

 

Quality
uses a series of 21 CFR Part 11 compliant software solutions to manage Quality activities as shown in the table below.

 

Table
C-2. QS Software Used at the ADM Facility

 

Quality Risk Management:

 

There
are two levels of Quality Risk Management (QRM) as defined in the QRM Procedure:

 

		1.	Level I QRM
                                            encompasses the policies, procedures and practices used to manage risk through implementation
                                            of the QMS and management reviews

		2.	Level II QRM
                                            encompasses product-specific risk management activities employed during the product development
                                            and post-marketing phases.

 

		n	Acceptance
                                            Activities: Identified hazards and related risk control measures are considered when
                                            developing criteria for verification and acceptance activities.
		n	Critical
                                            Quality Attributes (COAs): CQAs are determined for products which are incorporated into
                                            product specifications.

 

    	Ology Bioservices, Inc.	Proprietary
	27

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

Level
I QRM occurs through the following activities:

 

		n	Auditing
                                            Program: The auditing program provides information to management concerning effective
                                            implementation of the QS. Risk management principles are used to determine the frequency
                                            and scope of audits, both internal and external, considering factors such as results of previous
                                            audits/inspections, the complexity and inherent risks of the related processes and the number
                                            and significance of quality defects.

		n	Change Control: Proposed changes to
                                                                                                                                  products and processes are evaluated for their potential impact to product quality. The need for re-verification and/or
                                                                                                                                  re-validation is determined and the associated data reviewed prior to implementation of the change.

		n	Deviations:
                                            Deviations are assessed and classified based on the risk posed by the deviation to process
                                            and product quality. The level of investigation, priority of corrective actions and level
                                            at which deviations are reviewed are commensurate with the criticality of the deviation.
                                            Approval of a deviation occurs when the QA approver has determined that the identified corrective
                                            actions have adequately mitigated the risks posed by the deviation.

		n	Corrective
                                            and Preventive Actions (CAPA): The CAPA process is used to reveal any previously unrecognized
                                            risks and to monitor the effectiveness of risk control measures. CAPA information is used
                                            to determine the effectiveness of risk management activities and to determine the actions
                                            to be taken to correct identified issues and prevent recurrence.

		n	Manufacturing.
                                            Measuring and Monitoring Equipment: Suitability of equipment, qualification requirements,
                                            maintenance schedules and calibration requirements are determined based on the risks associated
                                            with the process. SOPs are developed, reviewed and updated to reflect appropriate control
                                            measures.

		n	Production
                                            and Process Control: Risk control measures employed to address hazards posed by equipment,
                                            processes, work environment and personnel are part of the production and process control
                                            procedures. Production and post-production information on products are continually monitored
                                            and analyzed. This includes the rate of non-conformities, the rate of rework, scrap and
                                            yield. This information is used to confirm the adequacy and completeness of risk controls.

		n	Critical
                                            Process Parameter (CCPs): Processes are evaluated to determine those CPPs which can affect
                                            CQAs. Once CPPs are identified, critical control points are identified, and in-process controls
                                            are implemented to mitigate risks from these process steps.

		n	Purchasing
                                            Controls: Purchasing requirements are used to control risks associated with suppliers.
                                            The criteria for selection, evaluation, and re-evaluation of suppliers are based on the level
                                            of risk associated with the products and services provided.

		n	Traceability:
                                            Risk management principles in conjunction with regulatory requirements are used to establish
                                            the criteria for traceability. All components, materials, and work conditions that could
                                            potentially cause a product not to satisfy its specified requirements are considered in establishing
                                            traceability criteria.

		n	Work
                                            Environment and Personnel: If the work environment or personnel are determined to pose
                                            a risk to products or processes, risk control measures are defined and implemented. The training
                                            process is used to ensure that personnel understand the implementation of risk control measures
                                            and the significance of their work with respect to product quality.

		n	Supplier
                                            Management: Potential suppliers are identified and placed into risk categories based
                                            on the impact of material or services on CGMP product and processes. Qualification of suppliers
                                            may include site audits and/or supplier quality survey based on the risk category.

		n	Concurrent
                                            Multiproduct Manufacturing: A process to evaluate risk associated for selection of new
                                            project, proposal development and introduction of samples, products or manufacturing campaigns
                                            has been developed. This process assesses the risk and identifies requirements for introducing
                                            and handling of new biologic, pharmaceutical or medical device sample, material, product
                                            or campaign into the ADM Facility. This process is intended to ensure client product quality
                                            and patient safety is maintained through reducing the risk of potential contamination and/or
                                            cross-contamination while preserving personnel and environmental safety conditions.

 

    	Ology Bioservices, Inc.	Proprietary
	28

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

Level
II QRM also includes design and process risks which are evaluated using tools such as Failure Modes Effects and Analyses. This process
includes a thorough breakdown of risks, followed by risk assessment and risk control in accordance with ICH guideline Q9 - QRM. Risk
assessment includes analysis and evaluation consisting of potential cause, severity, detection, occurrence, and current controls. Risk
control is the mitigation strategy for the identified risk. The ADM Facility is incorporating the principles of QRM described in ICH
Q9 into its QMS. The Facility has built the QRM elements into its QS processes including:

 

		n	Risk
                                            Identification

		n	Risk
                                            Assessment

		n	Risk
                                            Reduction

		n	Risk
                                            Acceptance

 

The
ADM Facility integrates these elements into its QS processes as demonstrated through quality records of impact assessments for deviations,
CAPA, and change control, and validation efforts which are utilized to make risk-based decisions commensurate with the consequences of
the risk to the safety of the patient.

 

Quality
Control:

 

The
ADM Facility has developed robust Quality Control (QC) systems and policies based on CGMP. Our team will provide Blue Water with the
highest quality products and services. QC is governed by the QS, which are applicable to the entire Facility site to ensure alignment
to the site Quality Philosophy. In addition, QC is controlled by a series of SOPs which specifically apply to operations that are unique
to QC laboratories.

 

The
Senior Director of QC manages the QC Department and is responsible for all environmental and utilities monitoring, in-process, release
and stability test programs and assuring that all testing is performed in accordance with applicable CGMP regulations. Key responsibilities
of the QC Department include:

 

		n	Control,
                                            distribution and disposal of product release, in-process and raw material test samples

		n	Qualification/validation
                                            of analytical methods, systems and equipment

		n	Performing
                                            QC release testing for raw materials, in-process control, Drug Substance, and Drug Product

		n	Reporting
                                            and approval of release and in-process test results

		n	Managing
                                            the stability test program

		n	Performing
                                            stability testing and preparing interim and final stability reports

		n	Participate
                                            in the establishment of specifications

		n	Performing/trending
                                            environmental and utilities monitoring testing

		n	Support
                                            qualification and manage analytical subcontractors

 

The QC Department consists of the
four functions outlined in the table below.

 

Table
C-3. QC Core Function

 

	Quality Group	Core Function
	 

    Sample
    Control/Stability
	●Receive,
    track and distribute test samples

    ●Manage
    the scheduling of stability sample testing

    ●Maintain
accurate inventoof sam Jes

	 

    QC
    Microbiology
	●Perform
    microbiological testing on finished product, bulk API and raw materials

    ●Responsible
    for the environmental and utilities monitoring program including collecting and testing samples and trending results

    ●Disinfectant
    efficacy

	QC
    Analytical Chemistry	●Perform
    physicochemical testing on finished product, bulk API and raw materials
	 

    QC
    Cell Assay
	●Perform
    immunoassays, cell-based assays and virology testing in support of in process and release

    ●Oversee
    testing for adventitious agents and animal testing performed for product

    release

 

    	Ology Bioservices, Inc.	Proprietary
	29

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

Equipment
Qualification, Calibration and Maintenance:

 

The
equipment in the QC laboratory is covered by the site-wide Qualification and Equipment Maintenance Programs to ensure that a fully CGMP-compliant
system across the site is qualified and included in the calibration and preventive maintenance programs. In addition, a QC equipment
program was implemented to address QC-specific instrument procedures. Operation and Maintenance (O&M) procedures are implemented
for all equipment and use of equipment is recorded in log books. Management of QC equipment calibration schedules are accomplished through
Ology Bio’s Calibration Program which includes procedures to ensure that equipment that is not appropriately qualified and calibrated
is tagged and taken out of service. Further, documentation procedures ensure that all data can be traced to the equipment on which it
was generated, so that data from malfunctioning equipment can be reliably identified.

 

Validation
and Qualification:

 

The
quality of the data from the QC laboratory relies on robust methods which are validated according to ICH and other applicable
guidelines. The competent and well-trained staff ensures the development of methods based on scientifically sound principles which
are appropriate for the product. Method development reports are prepared for all methods developed at the ADM Facility. Compendial
methods are verified at the Facility QC laboratories as required by USP <1226> and other compendia! chapters. Non-compendial
methods are subjected to phase appropriate qualification or validation according to applicable guidance.

 

Technical
Capabilities:

 

QC
serves as the raw material, in-process, and batch release testing and stability laboratories for products developed and/or manufactured
at the ADM Facility or transferred to ADM Facility for testing. Therefore, a wide range of products need to be handled by QC. These could
be well characterized vaccines generated by recombinant methods or complex products such as live vaccine products or polysaccharide conjugated
products which are not well characterized.

 

The
adherence to harmonized and CGMP procedures is ensured at the facility QC laboratory by implementation of effective SOPs. These SOPs
cover areas such as laboratory investigations, general procedures for handling reagents and reference standards, operation and maintenance
of equipment, the Stability Program, method validation, sample management and personnel training.

 

Where
the methods or expertise are not available in-house, the testing is out-sourced to reliable and approved laboratories. For example, all
required animal testing and adventitious agent testing are currently out-sourced. Methods that are expected to be only used for product/process,
development, product characterization or Drug Substance, such as Surface Plasmon Resonance for binding studies, Capillary Electrophoresis,
Analytical Ultra Centrifugation, LC-MS/MS, LC-QTOF-MS, Higher Order Analysis to include Circular Dichroisrn, Nano Differential Scanning
Calorimetry and Microflow Imaging are not currently planned to be implemented in the QC Department.

 

Contract
testing organizations used for out-sourced testing are assessed and approved through supplier approval program. Method development, transfer
and technical oversight is provided by QC functional area management. Sample management and distribution as well as communication of
results are managed by the QC Sample Control Department.

 

    	Ology Bioservices, Inc.	Proprietary
	30

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

Data
Management:

 

Information
security at Ology Bio is practiced at all levels in the organization and on all hardware and software. A combination of on premise
servers and cloud services are utilized for information processing. Information security of on premise systems and cloud systems is
assessed for each independent system. Appropriate controls are in place for workstations (laptops, desktops, thin clients), servers,
and network appliances. Leveraging industry best practices and National Institute of Standards and Technology (NIST) guidance
documentation, Ology Bio examines information security in six domains: Physical, Hardware, Software, Compliance and Procedural,
Personnel, Logical. These domains address topics such as identity verification, access controls, principle of least privilege,
physical security, antivirus, encryption, and various regulatory compliances.

 

Security:

 

Ology
Bio utilizes a layered approach to securing information. Detailed information on each security layer is further described below.

 

	1.	Physical:

		■	Access
                                            Control - The building has a proximity card access control system. Only employees and qualified
                                            vendors are allowed access to the building. The Information Technology (IT) closets also
                                            separately access controlled with limited individuals having access. There is a single entrance
                                            monitored by video and a security guard.

		■	Security-
                                            The building has 24-hour on-site security guards. At a minimum, there are two guards present.

			One
                                            monitors exterior perimeter, while the second monitors the interior. There is also constant
                                            video surveillance covering most of the building. The video software captures and records
                                            all motion events across all interior and exterior cameras.

		■	Fire
                                            Detection - The Facility has a dry-agent fire suppression system in all IT rooms to prevent
                                            damage to equipment. This system is monitored by the security operations center internally.

		■	Environmental
                                            Monitoring - The IT rooms are constantly monitored for temperature and humidity. In the event
                                            the air conditioner fails, and the room becomes too hot, the system immediately alerts the
                                            internal security office and IT staff.
	 	 	 

	2.	Hardware:

		■	Firewall,
                                            Intrusion Detection System (IDS), Intrusion Prevention System (IPS) - A redundant pair of
                                            Cisco ASAs is used as a firewall, IDS, and IPS. Security policies are only modified by the
                                            IT Department. In the event of a data breach, local authorities are contacted.

		■	Uninterruptable
                                            Power Supply- All servers and network equipment are run on the building’s UPS system. In
                                            the event of a power loss, the backup diesel generator activates to relieve the batteries.

		■	Redundant
                                            Hard Drives - All servers and storage utilize some version of Redundant Array of Independent
                                            Disks. This ensures that if a hard disk fails, the system will continue to operate normally
                                            until the disk is replaced.

		■	Off-Site
                                            Backups - A hardware backup appliance is used to backup data. The backup appliance stores
                                            a local copy of data and has the ability to tum on a virtual machine to mimic a server in
                                            case of catastrophic failure. This appliance also uploads encrypted and compressed data continuously
                                            to an off site data center.

		■	Disaster
                                            Recovery - Disaster recovery plans are in place in the event of catastrophic system failures.
                                            These plans will integrate with the business continuity plans.
	 	 	 

	3.	Software:

		■	End-Point
                                            Antivirus - All workstations and servers run a local anti-virus software. Virus definitions
                                            are updated daily. Only system administrators can stop the antivirus from running.

		■	Active
                                            Directory Security Policies - Various active directory security policies are in place to
                                            ensure data integrity. Active policies are based on government guidelines, including Federal
                                            Desktop Core Configuration/U.S. Government Configuration Baseline and Federal Information
                                            Processing Standards.

		■	Activity
                                            Logs - Active directory audits user logins and access attempts. These logs can be reviewed
                                            to determine if sensitive data is being accessed by unauthorized individuals.

		■	FDA
                                            21 CFR Part 11 - Often called ’‘Part 11 Compliance” is a special set of rules enabled
                                            in certain applications to enable the use of electronic signatures. Electronic signatures
                                            are utilized in applications such as the Enterprise Resources Planning software, Document
                                            Management Software, and Quality Management Software.

 

    	Ology Bioservices, Inc.	Proprietary
	31

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

		n	Software
                                            Patches and Updates - Software vendors publish security updates frequently to ensure the
                                            security of their products. These patches are enumerated by the IT Department, tested in
                                            a segregated network, and then pushed to appropriate users and computers.
	 	 	 

	4.	Compliance
                                 and Procedural:

		n	Regulatory
                                            Compliance - Various regulatory requirements require different levels of security. Needs
                                            of all regulatory bodies are reviewed and efforts made internally to meet them all.

		n	Change
                                            Control - A change control system is in place to prevent changing of network configurations.
                                            Configurations are locked by the IT Department, and changes are not made until the proper
                                            change control process, including impact assessments, is followed.

		n	SOPs
                                            - Various SOPs are in place governing the operation and maintenance of applications, network,
                                            and computer systems. All IT staff members are trained on appropriate SOPs before being given
                                            access.

		n	End-User
                                            Training - Training is provided to end-users before being granted access to the system. Training
                                            is also provided for new systems that may be launched. Records of all training are kept with
                                            each employee’s file.
	 	 	 

	5.	Personnel:

		n	Each
                                            new hire must complete an 19 form, present sufficient identification to verify identity,
                                            and have a background check performed. Depending on the position in the company, multiple,
                                            in-depth backgrounds checks may be run.
	 	 	 

	6.	Logical:

		n	A
                                            combination of Mandatory Access control and Discretionary Access Control is used to protect
                                            data confidentiality.

		n	The
                                            principle ofleast privilege is used when giving access to information systems.

		n	Privileged
                                            system accounts (e.g. administrator/root) are highly controlled and only used for appropriate
                                            purposes.

		n	Encryption
                                            is applied where required. TLS is implemented for sensitive email communication and on several
                                            internal software systems. Laptops and other mobile devices have their internal storage (e.g.
                                            hard drives) encrypted.

 

    	Ology Bioservices, Inc.	Proprietary
	32

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

APPENDIX
D - PROGRAM AND RISK MANAGEMENT

 

Our
commitment to client satisfaction and delivering high-quality work are our primary objectives. To achieve these objectives, experienced
technical and program management staff will lead the Ology Bio efforts, oversee subcontractors and represent us on an Integrated Product
Team (IPT) established with Blue Water. A Program Management Plan (PMP) will be generated to coordinate all aspects of the project plan.
The elements of the PMP will contain, at a minimum, the following:

 

		n	Project
                                            Charter - Establishes a collective understanding of the goals of the project as well as its
                                            governing ideals particularly regarding decision making and issue resolution.

		n	Communication
                                            Plan - The Project Manager (PM) is primarily responsible for project communication. The communication
                                            plan includes details on how project information will be disseminated to team members (internal
                                            weekly meetings, weekly client meetings)

		n	Integrated
                                            Master Schedule (IMS) - A detailed IMS using Microsoft Project will include all activities,
                                            deliverables and Go/No-Go decisions. The IMS will be updated and provided to Blue Water by
                                            the l0th of each month.

		n	Work
                                            Breakdown Structure (WBS)- A WBS will be generated that aligns with the scope and IMS.

		n	Cost
                                            Management/Budget Plan -A time-phase cost management/budget plan will detail the forecasted
                                            milestones and budget. The plan is updated monthly and provided to Blue Water by the 10th
                                            of each month.

 

Project
Charter:

 

The
project charter establishes a collective understanding of the goals of the project as well as its governing ideals particularly regarding
decision making and issue resolution. It provides formal authorization for the project and provides the PM with the authority to apply
organizational resources to conduct project activities. The charter references the purpose and goals of the project, project scope, success
criteria and specifies the team members from each contributing organization along with each person’s role on the project. It also provides
a description of the product along with key milestones, project risks, constraints and assumptions.

 

Product
Development Teams:

The
core members of the PDT include at a minimum the Principal Investigator (Pl), the PM, and the Finance Manager. The PM is ultimately responsible
for overall project management and communication, tracking performance, monitoring and reporting on project status and progress and facilitating
discussions on modifications to project requirements and timelines for the overall project. This includes management of work performed
internally and by subcontractors. The PM oversees the project budget, schedule, work scope and project risk planning and management.
Budget oversight is performed in close communication with the Financial Manager, who is ultimately responsible for financial management
of the program, and who provides financial reporting to the PM monthly. The core team also includes the Pl, who serves as the scientific
lead and communicates continuously and comprehensively with the PM and all technical support areas to ensure a technically sound program.

 

Given
the key role played by Ology Bio and the various subcontractors on this effort, our project teams have learned that a high-level of subcontractor
oversight leads to a high-quality product. Ology Bio uses robust processes and practices as well as appropriate point of contacts for
the project within both organizations to ensure success of the overall requirements management, project planning, project tracking and
project oversight along with the coordination of QA and Change Management.

 

The
PM maintains a continuous check on the overall program scope, schedule and budget as well as individual subcontractor schedules and budgets
to ensure contract compliance. The PM carefully monitors progress via continual communication with the PDT and by verifying the activity
accomplishment against the IMS. The PM schedules regular (weekly, bi-weekly or monthly as appropriate) team meetings to track open action
items and trace them to closure. The PI also ensures that each technical member of the team is meeting all technical requirements stated
in the contract. Interaction between the PM and the PI is of paramount importance and occurs continuously. Each one updates the other
with the status of items in their respective areas over the entire course of the project. When changes must be made to the schedule due
to scientific/technical issues, they coordinate revisions, risks, and costs together. Both also continuously assess risks and establish
mitigations to ensure success of the project.

 

    	Ology Bioservices, Inc.	Proprietary
	33

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

Functional
Members of the PDT:

Highly
specialized functional representatives will be chosen to support each PDT based on the skills needed to execute the work scope requirements.
This ensures that the PDT is fully capable of effectively planning a strategy to achieve licensure based on the expertise possessed by
members in all necessary product development areas. The PDT is the primary operational entity charged with successful start-up, implementation
and completion/ closeout of each project in alignment with the goals of the contract.

 

Each
PDT member has two reporting pathways in our matrixed management structure. Members report to both the functional department head and
the PDT. The effectiveness of a matrixed cross-functional team is dependent on continual structured communication between the PDT members
and senior management. The team uses this customized chain of command to identify, elevate and propose solutions to critical issues impacting
contract cost, schedule and scope. The PDT’s success hinges on the ability to interpret and react quickly to new technical data, changes
in FDA directives and/or business issues. Use of the cross-functional team structure, along with established communication pathways and
regular access to senior management ensures that the team operates effectively.

 

Our
senior management supports the mission of the PDT leadership by providing appropriate resources and guidance to maximize success. Management
also ensures that the teams do not function in isolation of each other; that is, information flows between PDTs to guarantee that lessons
learned, and best practices are equally disseminated not only as a form of risk management, but also as a means of continual process
improvement.

 

The
Integrated Project Team:

To
maximize efficiency and to ensure that all stakeholders in a program are fully represented, Ology Bio regularly employs an IPT
paradigm for oversight of projects. Establishment of the IPT is intended to facilitate effective communications for generating broad
awareness of project status and for decision making when the PDT requires guidance. The IPT will help to integrate all organizations
that have a stake in the performance of the project so that key decisions affecting the project/product are made with collective
awareness and buy-in. The IPT includes the PDT as well as members from Blue Water and any necessary technical resources that may be
employed on an ad hoc basis (consultants, academic investigators, etc.). In addition, subcontractors to the PDT may also be included
in the IPT, depending on the project scope (complexity) and the desires of the stakeholders.

 

The
team will provide technical, administrative and analytical support to the IPT as required. This will include, but not be limited to,
scheduling the meetings, creation of meeting agendas, meeting minutes, working notes, summaries, reports, analyses and briefing materials
as required. The IPT meetings will allow for sharing of specific information regarding the project timeline and deliverables status.
The IPT structure and composition is illustrated in Figure D-1.

 

    	Ology Bioservices, Inc.	Proprietary
	34

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

Figure
D-1. The Integrated Project Team

 

 

Project
Initiation:

The
project initiation phase requires a comprehensive review of the project scope and budget, official assignment of the PDT, verification
and finalization of the project IMS, IPT and project milestones and deliverables. In addition, project stakeholders and stakeholder
interfaces are determined, which will lead to subsequent creation of a Project Charter. A project kick-off meeting will be scheduled
within two weeks of signing, which will set the tone for the project and provide the team with the details necessary to begin conducting
work appropriately, as per the terms of the contract. Specific project initiation activities are detailed below.

 

Integrated
Master Schedule (IMS) Development:

The
IMS comprises the processes and core activities necessary for successful project execution and completion and is the primary tool used
by the PM to track and manage contract and project activities. Each activity in the IMS is assigned a WBS number to match the outline
of project work. The schedule includes a separate line item for each required activity along with planned start and finish dates. The
start date for each activity or task is driven by an appropriate linkage to a predecessor task or tasks. The finish dates are driven
by the duration of each task. The IMS cannot contain constraints, which will lead to an inaccurate critical path. The initial IMS for
a project is established by members of the PDT and will then be negotiated with Blue Water during the proposal negotiation phase.

 

A
more detailed schedule will be created after contract award. Once work begins, portions of our subcontractor’s schedules are
also inserted into the IMS so their activities will be added to the plan and tracked. The IMS includes the approved baseline
schedule and actual schedule as well as a column to indicate percentage completion for each task. Schedules are updated at least
monthly to show task progress and schedule slippage. The updated IMS will be provided in monthly reports to Blue Water.

 

    	Ology Bioservices, Inc.	Proprietary
	35

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

Meeting
Management:

 

Post-Award
Contract Initiation (Kick-Oft) Meeting:

A
post-award contract kick-off meeting will be scheduled within 14 calendar days following the effective date of contract award with all
key contract stakeholders. The kick-off meeting is conducted to establish a common purpose among stakeholders and to provide for a clear
understanding of the scope of the project, the schedule for key activities/milestones, the team roster and individual responsibilities,
appropriate communication pathways and the general administration of the project. The post award contract kick-off meeting will be a
one day meeting. The location for the meeting will be mutually determined. To support the post award contract kick off meeting, Ology
Bio will provide read-ahead materials, presentations, relevant documents, and an agenda. This meeting will be attended by Ology Bio key
personnel, designated Subject Matter Experts (SMEs), and investigator representatives. The PM will work with Blue Water to determine
timing and location for this meeting. PM will provide a meeting report within 7 calendar days after conduct of the meeting. This report
will include action items and due dates, any presentation materials as well as summaries of the discussions held.

 

PDT
Meetings:

The
PDT assigned to manage the contract will meet on a weekly schedule or as needed. These meetings will be focused on updates to critical
path activities and issue resolution. The PM will facilitate these meetings and will be responsible for capturing the meeting minutes
and for their distribution to the rest of the PDT. The PM will also be responsible for capturing action items and for ensuring that assigned
PDT members complete them on time.

 

IPT
Meetings:

The
PM will facilitate IPT meetings which will suffice as Progress Review Meetings to be attended by the essential members of the PDT, and
Blue Water’s staff to provide updates on contract performance. The PM will provide agendas for these meetings to all IPT members in advance.
The PM will capture minutes from all IPT teleconferences and will provide minutes within five business days.

 

Ad
Hoc Meetings:

Ad
hoc meetings will be held as necessary, upon team member or Client request, to discuss issues as they arise. Contract-related information
and updates will be provided to Blue Water upon request. Minutes from these meetings will also be provided as described above for IPT
meeting minutes.

 

Product-Specific
Risk Management Plan:

The
development of any product carries with it inherent risks that must be considered as part of the overall Program Management Plan. The
Ology Bio Project Risk and Opportunity Management Procedure governs how project risk management is conducted. The Ology Bio team views
risk management as a continuous project lifecycle activity and an integral and vital component of project management. Appropriate risk
planning and analysis will enable the PDT to think toward tomorrow, identify uncertainties, and anticipate potential outcomes, while
managing project resources and activities. Risk management, as performed by our team, includes the identification, assessment, and management
of areas that could affect our ability to achieve overall program objectives within the defined quality, cost, and schedule criteria
Assessing, mitigating, monitoring, and communicating risk events is a Ology Bio best practice conducted regularly on all our programs
to enhance our ability to eliminate or control project inefficiencies.

 

The
risk management methodology and processes that will be routinely utilized throughout the lifecycle of the project to include: Risk Identification,
Risk Analysis and Quantification, Risk Response Development, Risk Mitigation, Risk Monitoring, and Risk Response Control.

 

    	Ology Bioservices, Inc.	Proprietary
	36

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

Risks,
Risk Mitigation and Opportunities Identified:

 

The
PDT uses a well-defined, systematic, and iterative process to identify, assess, mitigate, and respond to areas that could prevent us
from meeting project objectives within the defined requirements. A robust risk management program is implemented throughout the
lifecycle of the program. At a very high level, the methodology and processes that will be routinely utilized include: Risk
Identification, Risk Assessment and Quantification, Risk Response Development, and Risk Response Control.

 

It
is important to note that we would prioritize the risks upon award to ensure that the focus is placed on the highest priority risks and
that appropriate resources are being applied to those first. It also bears mentioning that the preliminary Risk Assessment provided is
not a fully comprehensive list of potential risks, and that it is created to identify certain high-level risks experienced on other programs
and to be sure that all pertinent functional areas of the program are represented. The Risk Plan will be updated regularly, and continual
re-assessment of existing risks and their ratings will be required, to include the identification of new risks as work progresses.

 

Risk
Identification:

Under
the direction of the PM, the cross-functional PDT routinely uses proven risk management techniques to identify and assess all risk events
throughout the lifecycle of the project. Planning tools such as project requirements, product specifications, the technical approach,
costs and schedule baselines, product historical data, subcontractor insight, and regulatory agency requirements are all key inputs to
risk identification. As development progresses, complementary techniques to identify risks are part of other program activities such
routine status meetings and program reviews.

 

Risk
Assessment and Quantification:

The
PDT will evaluate the probability of occurrence and the potential impacts of each risk event on the project’s performance, schedule,
and cost objectives using numeric definitions on a scale of 1-5. The risk values will then be placed in a Risk Severity Matrix (RSM)
which defines the risk as low (green), medium (yellow), or high (red). Probability is based on understanding the requirements and performance
goals of each task order (TO) and is determined by quantifying the likelihood of occurrence. The overall likelihood that an event will
occur is estimated by combining data and the knowledge and experience of SMEs. The Risk Assessment Paradigm that we employed is illustrated
in Figure D-2 below.

 

Figure
D-2. Risk Assessment Paradigm

 

 

    	Ology Bioservices, Inc.	Proprietary
	37

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

During
risk analysis, the impact of a risk event occurring must be accurately predicted. Four primary areas are assessed to determine how severe
the impact is likely to be:

 

	1.	Impact
                                            on the Technical Performance: The most severe impact on a program is the impact on the
                                            product performance. The impact on the performance of the product is assessed based on how
                                            the risk will impact our ability to meet the requirements as defined in the contract.

 

	2.	Impact
                                            on the Activity Schedule: A risk event will ordinarily affect the time required to complete
                                            the activity affected. Any delay that a risk will cause to the project schedule is assessed
                                            based on lessons that Ology Bio has learned through other projects and the knowledge of the
                                            PDT. When assessing the impact to the project schedule, the time required for quality investigations
                                            and corrective/preventive actions are also taken into consideration.

 

	3.	Impact
                                            on the Program Schedule: When a risk event impacts the critical path, there is real potential
                                            for delays to the overall project schedule. This impact is assessed by considering whether
                                            the risk itself is on the critical path or whether it impacts other activities that are,
                                            and then estimating any additional time that would be required to recover from the risk event.

 

	4.	Impact
                                            on the Budgeted Cost of the Program: The PDT will calculate cost impact using the costs
                                            associated with the activities related to the risk event by determining the number of additional
                                            full-time equivalents required to complete work that would need to be repeated or new work
                                            that would be required if the risk event occurred as well as supplementary non-labor costs
                                            (materials, equipment, etc.). If the risk event is anticipated to push critical path an additional
                                            cost impact will be calculated based on an estimated project cost per day and delay period.
                                            Sequential to the risk cost impact, a risk-adjusted value is also determined. This is a budgeting
                                            tool that weighs the probability of the risk to determine the amount of money that should
                                            be put into the risk reserve as a precautionary measure.

 

Once
a risk event is assessed, the PDT will determine the overall severity or level of a risk by multiplying the risk probability by the combination
of the risk impacts. These calculations allow for prioritization of the risk events on the RSM and a determination of which risk events
justify the continued expenditure of time and effort on mitigation planning and execution.

 

Risk
Response Development:

The
key to risk mitigation is applying the appropriate action at the proper time. The RSM represents the magnitude of the risk and is
used to prioritize and select among alternative mitigation strategies. A feasible risk mitigation strategy is technically sound,
costs less than the cost impact if the risk event were to occur, does not create unacceptable delays, and does not adversely affect
the ability to meet performance or quality requirements. Risk mitigation activities help reduce or control the probability and/or
impact of a risk event.

 

When
risks are identified, and analyzed, it sometimes becomes evident that a contingency plan must also be developed to prepare for the
occurrence of an anticipated, problematic event. Using the RSM, the PDT will identify risks that are of a high enough probability
and/or impact to warrant contingency planning. In these cases, a preliminary contingency plan, containing a rudimentary description
of actions for responding to an undesirable occurrence will be developed. A triggering event, which may be a date, a set of
conditions, or a combination thereof, will be used to identify the conditions under which the contingency plan is to be further
developed and activated.

 

    	Ology Bioservices, Inc.	Proprietary
	38

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

Risk
Response Control:

The
selected mitigation strategies will be converted to a set of specific actions, and responsible parties assigned to each. The PM will
communicate regularly with the rest of the PDT to obtain mitigation statuses and will call meetings to allow the team to discuss the
effectiveness of the mitigation and reassess risk(s) as needed. In some cases, the team may determine that it is appropriate to further
develop the contingency plan at that time.

 

Risk
communication is at the heart of risk tracking and control. Risks will be discussed at regular project status meetings, and meetings
dedicated to risk planning. Anytime new activities are planned, risk is a routine consideration. The PM will present risk status and
proposed plans for risk mitigation and contingency at all product reviews throughout the lifecycle of the project, fully briefing Ology
Bio management on all serious risks, and ensuring that they are aware of those risks requiring external mitigation support.

 

Operational
Risk Management:

 

New
projects/programs transferred into the ADM Facility are reviewed and a risk assessment is conducted in accordance with established SOPs.
This assessment at a minimum evaluates safety, occupational health, disinfectant efficacy, cleaning validations, biowaste kill validations,
segregation concept as well as personnel, material and waste flows. Operational and safety hazards are assessed by the Biosafety Officer.
Contamination and cross contamination risks are assessed by QA. The outcome of these assessments is determined by the Institutional Biosafety
Committee.

 

Change
Management Plan (CMP):

 

The
Ology Bio Team understands that a CMP is needed to address project scope changes. This plan is generated according to our existing
SOP and a Change Request Form, crafted for use on the project based on client input, to ensure all proposed changes to authorized
scope are reviewed and approved in advance. This will include changes to the contract or to any subcontracted efforts. The CMP also
ensures all changes are evaluated appropriately and coordinated across the entire project and all stakeholders are notified of
approved changes. The plan will address how the project ensures changes are beneficial, determine how the change occur and allows
for management of the changes as they are implemented. Records of changes are maintained in the Product History File and documented
in the project Decision Log. This is of utmost importance when there are a number of changes required on a given project, so the PDT
understands what is in scope vs. out of scope.

 

The
change management process for a prime contract and for subcontracted efforts includes the same basic steps, as follows:

 

		l.	Submission
                                            of a written change request identifying and defining the proposed change;

		2.	Reason
                                            for the change;

		3.	Evaluation
                                            of the proposed change and its necessity;

		4.	Evaluation
                                            of any risks and/or impacts (cost, schedule, scope and/or quality) associated with the change;

		5.	Approval
                                            or rejection of the requested change in writing;

		6.	Modification
                                            of project plans to reflect the approved change;

		7.	Communication
                                            of the change to all affected parties.

 

The
individuals required for review and approval of proposed changes are defined within the Change Control Plan. This plan includes procedures
for handling emergency changes requiring approval and initiated without benefit of a full review.

 

    	Ology Bioservices, Inc.	Proprietary
	39

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

Deliverables
Acceptance Plan:

 

A
Deliverables Acceptance Plan will be created according to our existing model which includes a Deliverables Acceptance Form template for
use. The objective of the Deliverables Acceptance Plan is to provide a consistent format for describing project deliverables and specifying
the criteria for their acceptance in an appropriate amount of detail to allow for the straightforward determination of acceptability.
The plan will include the individuals responsible for review and acceptance and their roles in the acceptance management process. Objectives
of the plan includes ensuring the requirements and expectations of the project deliverables are clear to the PDT and that acceptance
is obtained in a timely manner to prevent undue delays. The Deliverables Acceptance Plan document is intended for use during the execution
and close-out phases of the project, and as such is used during each phase as deliverables are submitted to Blue Water, at the end of
the project, or both. The plan begins with identification, documentation and agreement by all key stakeholders with the quality requirements
of each project deliverable, to include required timing for delivery. After the deliverable review process, signature by the documented
review authorities indicates that the deliverable:

 

		n	Meets
                                            the specification;

		n	Has
                                            no significant unresolved issues;

		n	Meets
                                            the acceptance criteria;

		n	Is
                                            ready for release either as a baseline for subsequent work or as a stand-alone deliverable.

 

Reporting:

 

Monthly
Reports:

Ology
Bio will provide Monthly Technical Progress Reports, as required, to include an Executive Summary and updates on activities initiated
and/or completed during the reporting period as well as activities planned for future reporting periods. An overall progress, management
and administrative update, and technical progress section will be provided. The technical section will include subtask updates such as
cell banking, manufacturing processes, analytical assay development, and manufacturing run status. Updated financial information and
an updated IMS with percentage completion of required activities, and milestones will be included in the monthly reports. The monthly
report will be provided by the 10111 of each month.

 

Final
and Draft Reports:

Ology
Bio will provide documents through the course of contract execution, including, but not limited to, the following:

 

		n	Technical
                                            and Scientific Development Reports

		n	Assay
                                            SOPs and Qualification Reports

		n	Master
                                            Production Records

		n	Executed
                                            Batch Records

		n	Certificates
                                            of Analysis

		n	Campaign
                                            Summary Report

		n	Stability
                                            Reports

		n	Microsoft
                                            Word documents in CTD format to support regulatory filings

 

Ology
Bio will submit a draft report summarizing all the work performed on the contract to cover the full contract scope and period of
performance. The report will describe the salient results achieved in the work conducted. The draft will be submitted for review
within 30 days following completion of the study unless otherwise agreed to in the IMS and will be edited into the final report
after comments have been received. Ology Bio assumes that the first draft will be due to Blue Water at least 30 calendar days prior
to completion of the last contracted activity, one round of review and a two-week turnaround for receipt of comments. The final
report will be submitted within 7 calendar days after receipt of client comments on the draft report.

 

Subcontract
Management:

 

Ology
Bio uses acquisition planning as an integral part of our proposal efforts to identify subcontractors that best meet the needs and scope
of work for our clients. Ology Bio has an approved purchasing system and follows Procurement SOPs to facilitate fair competition. The
technical team provides a detailed Statement of Work (SOW) and list of companies to the Procurement Department personnel. Procurement
prepares the Request for Proposal containing the SOW, Standard Terms and Conditions, Vendor Qualification form and, if applicable, a
Quality Vendor Application.

 

    	Ology Bioservices, Inc.	Proprietary
	40

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

Upon
receiving the subcontractor proposals, the Procurement team will review them for compliance and then distribute to the technical team.
The technical team will evaluate each bidder’s technical approach; personnel and project management; facility and resources; cost/price;
schedule and quality assurance, and then completes a technical evaluation form. Once the technical evaluation is completed, Procurement
conducts a best value review, which includes a source analysis; performance evaluation; a cost/price analysis of the bids provided and
an assessment of the bid process.

 

Our
project teams have learned that a high-level of subcontractor oversight leads to a high-quality product. The PM is ultimately responsible
for management of work performed by the subcontractor. Once work begins, portions of our subcontractor’s schedules are inserted into
the IMS so their activities will be added to the plan and tracked. The PM maintains a continuous check on the individual subcontractor
schedules and budgets to ensure contract compliance.

 

Subcontractor
Risk Management:

Each
supplier providing services or materials to Ology Bio goes through a risk assessment process. Ology Bio puts suppliers into categories
based on the potential impact the service or material provided will have on product quality or regulatory compliance. Suppliers with
the greatest potential impact are placed in the highest risk classification (i.e., subcontractors conducting CGMP or GLP services). Quality
Agreements are established for all suppliers in this classification that defines the quality requirements and responsibilities of each
organization.

 

    	Ology Bioservices, Inc.	Proprietary
	41

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

APPENDIX
E - RELEVANT COMPANY EXPERIENCE

 

From
its beginnings, Ology Bio’s growth was fueled through grants and contracts from both industry and several U.S. Government (USG) agencies.
Today, Ology Bio has grown to nearly 200 employees located in three U.S. locations.

 

On
March 30, 2013, The Department of Defense (DoD) awarded Ology Bio and its team of partners and collaborators, a contract to provide all
the core services necessary to establish a Medical Countermeasures Advanced Development and Manufacturing (MCM ADM) Facility dedicated
to meet the specific needs of the DoD. The 10-year, $400+ million contract had a base period goal for the construction of an 180,000
ft2, state of-the-art, BSL-3, single-use facility that the Ology Bio now occupies and operates.

 

On
September 25, 2013, The Biomedical Advanced Research and Development Authority, within the Office of the Assistant Secretary for Preparedness
and Response in the U.S. Department of Health and Human Services established a fill and finish network. Ology Bio was awarded a prime
contract to partner with a pandemic influenza vaccine manufacturer to transfer the fill and finish contract manufacturers technology
into its existing facilities to provide surge capacity for drug shortage and emergency pandemic response products (e.g., anti Ebola monoclonal
antibody, pandemic influenza vaccine). Ology Bio’s expanded fill and finish network can provide these core services for manufacturers
of drugs and vaccines intended to treat and protect public health against chemical, biological, radiological and nuclear threats.

 

    	Ology Bioservices, Inc.	Proprietary
	42

    
	Process Development and Manufacture Influenza Vaccine Candidate	 	Rev 02; May 22, 2019

 

    

 

AS
WITNESS this agreement has been signed by the duly authorised representatives of the parties.

 

	SIGNED for and
    on behalf of	 	SIGNED for
    and on behalf of
	OXFORD UNIVERSITY
    INNOVATION 

    LIMITED:	 	BLUE WATER VACCINES
    INCORPORATED:
	 	 	
	Name:	DR PAUL ASHLEY

HEAD OF TECHNOLOGY TRANSFER

LIFE SCIENCES

OXFORD UNIVERSITY INNOVATION LTD
	 	Name:	Joseph
    Hernandez
  
	Position:	 	Position:
	Signature: 	/s/ Paul ashley	 	Signature: 	/s/ Joseph
    Hernandez
	Date:	16/7/19	 	Date:	7/3/2019
	 	 	 
	 	 	 

 

    	Ology Bioservices, Inc.	Proprietary
	43Exhibit 10.10

 

Certain portions of this exhibit have been omitted pursuant to
Rule 601(b)(10) of Regulation S-K The omitted information is (i) not material and (ii) would likely cause competitive harm to Blue Water
Vaccines, Inc. if publicly disclosed. Information that has been omitted has been noted in this document with a placeholder identified
by the mark “[***]”.

 

EXCLUSIVE LICENSE AGREEMENT

BETWEEN

ST. JUDE CHILDREN’S RESEARCH
HOSPITAL, INC.

 

&

 

BLUE WATER VACCINES

 

ST. JUDE File No.: SJ-11-0001
and SJ-18-0045

 

    

     

    

 

LICENSE AGREEMENT

 

THIS LICENSE AGREEMENT (the
“Agreement”) is entered into as of January 27, 2020 (the “EFFECTIVE DATE”) by and between ST. JUDE
CHILDREN’S RESEARCH HOSPITAL, INC., a Tennessee not-for-profit corporation having an address at 262 Danny Thomas Place,
Memphis, TN 38105 (“ST. JUDE” or “LICENSOR”), and Blue Water Vaccines, Inc., a Delaware corporation, having
an address at 2014 Courtland Avenue, Cincinnati, OH 06830 (“COMPANY”) (ST. JUDE and COMPANY hereinafter each referred to
as a “PARTY”, or collectively referred to as the “PARTIES”) with respect to the following:

 

RECITALS

 

WHEREAS, as
a center for research and education, ST. JUDE is interested in licensing PATENT RIGHTS (hereinafter defined) in a manner that will benefit
the public by facilitating the development of useful products; and

 

WHEREAS, the
valuable invention(s) titled “Live, Attenuated Streptococcus Pneumoniae Strain and Vaccine for Protection Against Pneumococcal
Disease” (ST. JUDE File No.: SJ-11- 0001) and “Vaccine Compositions and Methods for Reducing Transmission of Streptococcus
Pneumoniae” (ST. JUDE File No.: SJ-18-0045) were developed during the course of research conducted by Dr. Jason Rosch and other
members of ST. JUDE (all hereinafter referred to as “INVENTORS” and each individually referred to as an “INVENTOR”);
and

 

WHEREAS, LICENSOR
has acquired through assignment by each of the INVENTORS all rights, title and interest, with the exception of certain retained rights
by the United States Government, in their interest in said valuable inventions; and

 

WHEREAS, COMPANY
desires to obtain certain rights in such inventions as herein provided, and to provide funding for research related to such inventions
at ST. JUDE, if applicable, subject to the terms of a research collaboration agreement(s) to be negotiated by the PARTIES, and to commercially
develop, manufacture, use and/or distribute products based upon or embodying said valuable inventions throughout the world; and

 

    2

     

    

 

NOW THEREFORE,
in consideration of the premises and the mutual promises and covenants contained in this Agreement, and for other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the PARTIES hereto agree as follows:

 

ARTICLE 1

DEFINITIONS

 

All references to particular
Exhibits, Articles or Paragraphs shall mean the Exhibits to, and Paragraphs and Articles of, this Agreement, unless otherwise specified.
For the purposes of this Agreement and the Exhibits hereto, the following words and phrases shall have the following meanings:

 

1.1 AFFILIATED
COMPANY” as used herein in either singular or plural shall mean any corporation, company, partnership, joint venture or other
entity, which controls, is controlled by or is under common control with COMPANY. For purposes of this Paragraph 1.1, control shall mean
the direct or indirect ownership of at least fifty- percent (50%) of the voting or economic interest in said entity. Any AFFILIATED COMPANY
that is exercising rights under this AGREEMENT shall provide a written acknowledgement to LICENSOR that they are bound by, and agree to
abide by, the terms of this AGREEMENT.

 

1.2 EFFECTIVE
DATE” of this License Agreement shall mean the date set forth above.

 

1.3 EXCLUSIVE
LICENSE” shall mean a grant by LICENSOR to COMPANY of their entire right and interest in the PATENT RIGHTS subject to the exceptions
set forth in Article 2.

1.4 FIRST
COMMERCIAL SALE” shall mean the first sale for use or consumption by the general public of LICENSED PRODUCT in a country after
regulatory approval has been obtained for such LICENSED PRODUCT in such country.

 

1.5 IND”
shall mean an Investigational New Drug application filed with the Food and Drug Administration for authorization to commence human
clinical trials in the United States, and its equivalent in other countries or regulatory jurisdictions.

 

1.6
“LICENSED FIELD” shall mean vaccines for use in humans.

 

1.7 LICENSED
PRODUCT(S)” as used herein in either singular or plural shall mean any material, compositions, drug, or other product, the manufacture,
use or sale of which would constitute, but for the license granted to COMPANY pursuant to this Agreement, an infringement of a VALID CLAIM
of PATENT RIGHTS (infringement shall include, but is not limited to, direct, contributory, or inducement to infringe).

 

1.8 NET
SALES” shall mean gross sales revenues and fees billed by COMPANY, AFFILIATED COMPANY and SUBLICENSEE(S) from the sale of LICENSED
PRODUCT(S) less the following:

 

(a) customary
trade, quantity, or cash discounts to the extent actually allowed and taken;

 

(b) amounts
repaid or credited by reason of rejection or return of LICENSED PRODUCTS;

 

(c) to
the extent separately stated on purchase orders, invoices, or other documents of sale, any taxes or other governmental charges levied
on the production, sale, transportation, delivery, or use of a LICENSED PRODUCT, which is paid by or on behalf of COMPANY or AFFILIATES;
and

 

(d)
outbound transportation costs prepaid or allowed and costs of insurance in transit.

 

    3

     

    

 

For purposes
of determining NET SALES, the LICENSED PRODUCT(S) shall be deemed to be sold when invoiced and a “sale” shall not include
transfers or dispositions for charitable, promotional, pre-clinical, clinical, regulatory or governmental purposes.

 

1.9 PATENT
RIGHTS” shall mean U.S. provisional patent application no. 61/537,290, titled “Live, Attenuated Streptococcus Pneumoniae
Strain and Vaccine for Protection Against Pneumococcal Disease” filed on September 21, 2011, which issued as US patent number 9,265,819
on February 23, 2016 and U.S. provisional patent application no. 62/817,748 filed March 13, 2019 owned by LICENSOR and all invention(s)
disclosed and claimed therein (“INVENTION”), and any issued patents, divisions, continuations, continuations-in-part to the
extent that the claims are directed to subject matter described in the above-referenced patent applications and are entitled to the priority
date of the existing PATENT RIGHTS, reexaminations, substitutions, renewals, restorations, additions or registrations thereof, as well
as non-United States counterparts thereof and extensions and supplementary protection certificates thereon.

 

1.10 PHASE
I CLINICAL TRIAL” shall mean a human clinical trial, the principal purpose of which is a preliminary determination of safety
in healthy individuals or patients as required in 21 C.F.R. §312, or a similar clinical study prescribed by the regulatory authorities
in a country other than the United States.

 

1.11 PHASE
II CLINICAL TRIAL” shall mean (i) a human clinical trial, for which a primary endpoint is a preliminary determination of efficacy
or dose ranges in patients with the disease target being studied as required in 21 C.F.R. §312.21(b), as may be amended from time
to time, or a similar clinical study prescribed by the regulatory authorities in a country other than the United States, or (ii) a combined
Phase II and Phase III Clinical Trial which enrolls at least forty (40) patients, or any Phase III Clinical Trial performed in lieu of
a Phase II study.

 

1.12 PHASE
III CLINICAL TRIAL” shall mean a human clinical trial, the principal purpose of which is to establish safety and efficacy in
patients with the disease target being studied as required in 21 C.F.R. §312, or similar clinical study prescribed by the regulatory
authorities in a country other than the United States. A Phase III Clinical Trial shall also include any other human clinical trial intended
as a pivotal study, whether or not such study is a traditional Phase III study.

 

1.13 SUBLICENSEE(S)”
as used herein in either singular or plural shall mean any person or entity other than an AFFILIATED COMPANY to which COMPANY has
granted a sublicense of PATENT RIGHTS under this Agreement.

 

1.14 VALID CLAIM” as
used herein in either singular or plural shall mean a claim of any (i) issued and unexpired patent included within the PATENT RIGHTS
unless the claim has been held unenforceable or invalid by the final, un-reversed, and un-appealable decision of a court or other
government body of competent jurisdiction, has been irretrievably abandoned or disclaimed, or has otherwise been finally admitted or
determined to be invalid, unpatentable or unenforceable, whether through reissue, reexamination, disclaimer or otherwise, or (ii) a
pending claim of a patent application within the PATENT RIGHTS to the extent the claim continues to be prosecuted in good faith and
has not been cancelled, withdrawn, abandoned or finally disallowed without the possibility of appeal or re-filing of such
application.

 

    4

     

    

 

ARTICLE
2

LICENSE GRANT

 

2.1 Grant.
Subject to the terms and conditions of this Agreement, LICENSOR hereby grants to COMPANY an EXCLUSIVE LICENSE to develop, make, have made,
use, import, offer for sale and sell the LICENSED PRODUCT(S) worldwide under the PATENT RIGHTS in the LICENSED FIELD. This license grant
shall apply to the COMPANY and any AFFILIATED COMPANY, except that any AFFILIATED COMPANY shall not have the right to sublicense others
as set forth in Paragraph 2.2 below. If any AFFILIATED COMPANY exercises rights under this Agreement, such AFFILIATED COMPANY shall be
bound by all terms and conditions of this Agreement, including, but not limited to, indemnity and insurance provisions and royalty and
other payment provisions, which shall apply to the exercise of the rights, to the same extent as would apply had this Agreement been directly
between LICENSOR and the AFFILIATED COMPANY. In addition, COMPANY shall remain fully liable to LICENSOR for all acts and obligations of
AFFILIATED COMPANY such that acts of the AFFILIATED COMPANY shall be considered acts of the COMPANY.

 

2.2
Sublicense. COMPANY may grant sublicenses under the PATENT RIGHTS to third parties under
this Agreement, subject to the terms and conditions of this Paragraph 2.2. COMPANY shall provide LICENSOR with a redacted
confidential copy of each sublicense agreement between COMPANY and a third party for the grant of rights under the PATENT RIGHTS
within forty-five (45) days of its execution. Each sublicense agreement shall: (a) be consistent with the terms, conditions and
limitations of this Agreement, (b) name LICENSOR as an intended third party beneficiary of the obligations of SUBLICENSEE without
imposition of obligation or liability on the part of LICENSOR or the INVENTORS to the SUBLICENSEE, (c) specifically incorporate
Paragraphs 6.2 “Representations by LICENSOR”, 7.1 “Indemnification”, 10.1 “Use of Name”, and
10.4 “Insurance” into the body of the sublicense agreement, and cause the terms used therein to have the same meaning as
in this Agreement, and (d) permit the SUBLICENSEE to grant further sublicenses, provided that such sub-sublicensees shall be
subject to all of the terms and conditions of this Paragraph 2.2. The redacted copy of each sublicense agreement or sub-sublicense
agreement furnished to LICENSOR by COMPANY shall be the Confidential Information of COMPANY. COMPANY shall (a) be and remain
responsible for the performance by such SUBLICENSEE, and such SUBLICENSEE’s sublicensees, with the terms of this Agreement,
and any action by a SUBLICENSEE, and such SUBLICENSEE’s sublicensees, that would, if conducted by COMPANY, be a breach of this
Agreement, shall be deemed a breach of this Agreement by COMPANY, and (b) ascertain, calculate, audit and collect all royalties that
become payable by such SUBLICENSEE, and such SUBLICENSEE’s sublicensees, hereunder and take appropriate enforcement action
against such SUBLICENSEE, and such SUBLICENSEE’s sublicensees, for any failure to pay or to properly calculate payments.

 

For the avoidance of doubt, an agreement between
any of COMPANY, an AFFILIATED COMPANY or a SUBLICENSEE and a third party granting rights (in the absence of consideration to
COMPANY, AFFILIATED COMPANY, or SUBLICENSEE) to the third party to perform research or development activities solely on behalf of
COMPANY, AFFILIATED COMPANY, or SUBLICENSEE, but not rights to commercialize or otherwise exploit LICENSED PRODUCTS, shall not be
deemed to be a sublicense hereunder and shall not be subject to the terms of this Paragraph 2.2; provided, however, that COMPANY
will remain solely responsible for such agreements and the actions of any party it contracts with thereunder.

 

2.3 Government
Rights. The United States Government may have acquired a nonexclusive, nontransferable, irrevocable, paid-up license to practice or
have practiced for or on behalf of the United States the INVENTIONS described in PATENT RIGHTS throughout the world. The rights granted
herein are additionally subject to: (i) the requirement that any LICENSED PRODUCT(S) produced for use or sale within the United States
shall be substantially manufactured in the United States (unless a waiver under 35 USC § 204 or equivalent is granted by the appropriate
United States government agency), (ii) the right of the United States government to require LICENSORS, or their licensees, including COMPANY,
to grant sublicenses under the PATENT RIGHTS to responsible applicants on reasonable terms when necessary to fulfill health or safety
needs, and, (iii) other rights acquired by the United States government under the laws and regulations applicable to the grant/contract
award under which the inventions were made.

 

2.4 LICENSOR Retained
Rights. LICENSOR retains the right to make, have made, provide and use for LICENSOR’S non-commercial research and clinical
purposes, including the ability to distribute LICENSOR’S biological materials disclosed and/or claimed in PATENT RIGHTS for nonprofit
academic research use to non-commercial entities as is customary in the scientific community and to sell the biological materials as
research reagents for research use only by the scientific community.

 

    5

     

    

 

ARTICLE 3

FEES, ROYALTIES, & PAYMENTS

 

3.1 License
Fee. COMPANY shall pay to LICENSOR within thirty (30) days of the EFFECTIVE DATE a license fee as set forth in Exhibit A. LICENSOR
will not submit an invoice for the license fee, which is nonrefundable and shall not be credited against royalties or other fees.

 

3.2 Annual
Maintenance Fee. COMPANY shall pay to LICENSOR the annual maintenance fee as set forth in Exhibit A. These annual maintenance
fees shall be due, without invoice from LICENSOR, within thirty (30) days each anniversary of the EFFECTIVE DATE beginning with the first
anniversary. Running royalties and Milestone Payments accrued under, respectively, Paragraph 3.3 and Paragraph 3.5 and paid to LICENSOR
during the preceding calendar year shall be credited against the minimum annual royalties due the following year. For example, running
royalties and milestone payments accrued under and paid to LICENSOR during calendar year 2020 shall be credited against the annual maintenance
fee due and payable no later than January 30, 2021.

 

3.3 Running
Royalties. COMPANY shall pay to LICENSOR a running royalty as set forth in Exhibit A, for each LICENSED PRODUCT(S) sold by
COMPANY, AFFILIATED COMPANIES and/or SUBLICENSEE(S), based on NET SALES for the term of this Agreement. Such payments shall be made quarterly.
All non-US taxes related to LICENSED PRODUCT(S) sold under this Agreement shall be paid by COMPANY and shall not be deducted from royalty
or other payments due to LICENSOR.

 

In order to
insure LICENSOR the full royalty payments contemplated hereunder, COMPANY agrees that in the event any LICENSED PRODUCT(S) shall be sold
to a corporation, firm or association (the “PURCHASER”) with which COMPANY shall have any agreement, understanding or arrangement
with respect to consideration (such as, among other things, an option to purchase stock or actual stock ownership, or an arrangement involving
division of profits or special rebates or allowances) received by COMPANY with respect to sale of such LICENSED PRODUCT(S), the royalties
to be paid hereunder to LICENSOR for such LICENSED PRODUCT(S) shall be based upon the greater of: 1) the net selling price (per NET SALES)
at which the PURCHASER resells such LICENSED PRODUCT(S) to the end user, 2) the fair market value of the LICENSED PRODUCT(S) as of the
date that COMPANY receives such consideration from such PURCHASER, or 3) the net selling price (per NET SALES) of LICENSED PRODUCT(S)
paid by the PURCHASER.

 

3.4 Sublicense
Consideration. In addition to the running royalty as set forth under Paragraph 3.3, COMPANY shall pay to LICENSOR, as set forth on
Exhibit A a percentage of consideration received for sublicenses (collectively, “SUBLICENSE CONSIDERATION” as further
defined below in this Paragraph 3.4) under this Agreement, solely to the extent that such consideration relates to the value of a sublicense
to the PATENT RIGHTS but (i) subject to the limitations set forth below and (ii) excluding consideration that relates to the value of
other intellectual property rights licensed by COMPANY to such SUBLICENSEE. This SUBLICENSE CONSIDERATION shall be due, without the need
for invoice from LICENSOR, within forty-five (45) days of the receipt of any SUBLICENSE CONSIDERATION payment made to COMPANY by a SUBLICENSEE
under a sublicense agreement. Such SUBLICENSE CONSIDERATION shall mean consideration of any kind received by the COMPANY from a SUBLICENSEE(S)
for the grant of a sublicense under this Agreement, such as upfront fees or milestone fees and including any premium paid by the SUBLICENSEE(S)
over Fair Market Value (as such term is defined in Paragraph 3.3(c) below) for stock of the COMPANY in consideration for such sublicense.
However, not included in such SUBLICENSE CONSIDERATION are:

 

		(a)	Support for research, development (product development, clinical studies and regulatory), and/or manufacturing
activities corresponding directly to the development of LICENSED PRODUCT(S), which do not exceed the fully- burdened cost for undertaking
such research, development, and/or manufacturing performed by or for the COMPANY or AFFILATED COMPANY (including third parties on their
behalf), each pursuant to a specific agreement including a performance plan and commensurate budget;

 

		(b)	Proceeds derived from debt financing, to the extent that such financing is at market rates, and any loans
to COMPANY or AFFILIATED COMPANY by SUBLICENSEE:

 

		(c)	Consideration received for the purchase of an equity interest in COMPANY to the extent that the price
per share for such equity does not exceed by more than twenty-five percent (25%) the Fair Market Value of COMPANY’s stock. The term
Fair Market Value shall mean the average price that the stock in question is publicly trading at for twenty (20) days prior to the announcement
of its purchase by the SUBLICENSEE(S) or if the stock is not publicly traded, the value of such stock as determined by the most recent
private financing through a financial investor (an entity whose sole interest in the COMPANY or AFFILIATED COMPANY is financial) of the
COMPANY or AFFILIATED COMPANY that issued the shares;

 

    6

     

    

 

		(d)	As reimbursement of COMPANY’s patent costs related to PATENT RIGHTS;

 

		(e)	Amounts paid to the COMPANY or AFFILIATED COMPANY by the SUBLICENSEE(S) for royalties on Licensed Products
which are subject to payments to LICENSOR under Paragraph 3.3.

 

3.5 Milestone
Payments. COMPANY shall pay to LICENSOR the milestone payments as set forth in Exhibit B for the term of this Agreement. All
non-US taxes (excluding any taxes based on LICENSOR’S income) related to milestone payments shall be paid by COMPANY and shall not
be deducted from payments due to LICENSOR.

 

3.6 Patent
Reimbursement. COMPANY will reimburse LICENSOR, within thirty (30) days of the EFFECTIVE DATE the amount of $ [***] for costs
associated with the preparation, filing, maintenance, and prosecution of PATENT RIGHTS in the LICENSED FIELD incurred by LICENSOR on
or before January 27, 2020. In accordance with Paragraph 4.1 below, COMPANY will reimburse LICENSOR, within thirty (30) days of the
receipt of an invoice from LICENSOR, for all reasonable costs associated with the preparation, filing, maintenance, and prosecution
of PATENT RIGHTS in the LICENSED FIELD incurred by LICENSOR subsequent to January 28, 2020. Each invoice submitted to COMPANY by
LICENSOR shall include copies of the actual invoices from LICENSOR’S patent counsel.

 

3.7 Form
of Payment. All payments under this Agreement shall be made in U.S. Dollars. Checks are to be made payable to “St. Jude Children’s
Research Hospital”. Wire transfers may be made using the following information:

 

Acct Name: St. Jude Children’s Research Hospital,
Master Concentration Account

Acct Number: 00-0270040

Bank Name: First Tennessee

Bank Bank Swift: FTNMUS44

Bank ABA #: 084-000026

Bank Address: Post Office Box 84

Memphis, TN 38101

USA

 

COMPANY shall
be responsible for any and all costs associated with wire transfers and shall include a reference to this Agreement in any wire transfer
payment. Payments made by check should be sent to the following address:

 

St. Jude Children’s Research Hospital

P.O. Box 1000, Department # 516

Memphis, TN 38148-0516

 

3.8 Late
Payments. In the event that any payment due hereunder is not made when due, the payment shall accrue interest beginning on the tenth
day following the due date thereof, calculated at the annual rate of the sum of (a) two percent (2%) plus (b) the prime interest rate
quoted by The Wall Street Journal on the date said payment is due, the interest being compounded on the last day of each calendar quarter,
provided however, that in no event shall said annual interest rate exceed the maximum legal interest rate for corporations. Each such
payment when made shall be accompanied by all interest so accrued. Said interest and the payment and acceptance thereof shall not negate
or waive the right of LICENSOR to seek any other remedy, legal or equitable, to which it may be entitled because of the delinquency of
any payment including, but not limited to termination of this Agreement as set forth in Paragraph 9.2.

 

    7

     

    

 

ARTICLE 4

PATENT PROSECUTION, MAINTENANCE,
& INFRINGEMENT

 

4.1 Prosecution &
Maintenance. COMPANY will bear all expenses relating to the filing, prosecution, and maintenance of all PATENT RIGHTS after the
EFFECTIVE DATE. Upon approval of the law firm by LICENSOR, COMPANY may oversee future patent prosecution using its patent counsel
and pay patent expenses directly, so long as LICENSOR is copied on all correspondence and notified prior to any substantive actions.
Title to all patents and patent applications shall reside in LICENSOR. COMPANY shall (a) cause its patent counsel to timely copy
LICNESOR on all official actions and written correspondence with any patent office, and (b) allow LICENSOR and/or its counsel an
opportunity and reasonably sufficient time to comment and advise COMPANY with respect thereto. COMPANY shall consider in good faith
and reasonably incorporate all comments and advice from LICENSOR. At least thirty (30) days in advance of any filing or response
deadline, or fee due date, COMPANY may elect not to have a patent application filed in any particular country or not to pay expenses
associated with prosecuting or maintaining any patent application or patent within PATENT RIGHTS, provided that COMPANY pays for all
costs incurred up to LICENSOR’S receipt of such notification. Failure to provide such notification will be considered by
LICENSOR to be COMPANY’s willingness to proceed at COMPANY’s expense. Upon such notification, at LICENSOR’S own
expense, LICENSOR may file, prosecute, and/or maintain such patent applications or patent within the PATENT RIGHTS with respect to
which COMPANY has made the foregoing decision(s) (collectively, the “COMPANY-ABANDONED PATENTS”), and any rights or
license granted hereunder held by COMPANY, AFFILIATED COMPANIES or SUBLICENSEE(S) relating to COMPANY-ABANDONED PATENTS shall
terminate.

 

4.2 Notification.
Each PARTY will notify the other promptly in writing when any infringement by a third party is uncovered or suspected.

 

4.3 Infringement.
COMPANY shall have the first right to enforce any patent within PATENT RIGHTS against any infringement or alleged infringement thereof,
and shall at all times keep LICENSOR informed as to the status thereof. Before COMPANY commences an action with respect to any infringement
of such patents, COMPANY shall give careful consideration to the views of LICENSOR and to potential effects on the public interest in
making its decision whether or not to sue. Thereafter, COMPANY may, at its own expense, institute suit against any such infringer or alleged
infringer and control and defend such suit in a manner consistent with the terms and provisions hereof and recover any damages, awards
or settlements resulting therefrom, subject to Paragraph 4.5. However, no settlement, consent judgment or other voluntary final disposition
of the suit may be entered into without the prior written consent of LICENSOR, which consent shall not be unreasonably withheld. This
right to sue for infringement shall not be used in an arbitrary or capricious manner. LICENSOR shall reasonably cooperate in any such
litigation at COMPANY’s expense.

 

If COMPANY elects not to enforce
any patent within the PATENT RIGHTS, then it shall so notify LICENSOR in writing within ninety (90) days of receiving notice that an infringement
exists. LICENSOR may, in its sole judgment and at its own expense, take steps to enforce any patent and control, settle, and defend such
suit in a manner consistent with the terms and provisions hereof, and recover, for its own account, any damages, awards or settlements
resulting therefrom. Before LICENSOR commences an action with respect to any infringement of such patents, LICENSOR shall give careful
consideration to the views of COMPANY and to potential effects on COMPANY’S interests under this Agreement in making its decision
whether or not to sue and thereafter shall at all times keep COMPANY informed as to the status thereof, as long as COMPANY is licensed
under said patents.

 

4.4 Patent
Invalidity Suit. If a declaratory judgment action is brought naming COMPANY as a defendant and alleging invalidity of any of the PATENT
RIGHTS, LICENSOR may elect to take over the sole defense of the action at its own expense. COMPANY shall cooperate fully with LICENSOR
in connection with any such action. LICENSOR shall give careful consideration to the views of COMPANY and to potential effects on COMPANY’S
interests under this Agreement in any such defense and thereafter shall at all times keep COMPANY informed as to the status thereof, as
long as COMPANY is licensed under said patents.

 

    8

     

    

 

4.5 Recovery. In any
action taken pursuant to Section 4.3, COMPANY and LICENSOR shall recover their respective actual out-of-pocket expenses (including
attorneys’ fees), or equitable proportions thereof, associated with the action or settlement thereof from any resulting
recovery made by either PARTY with the PARTY controlling the action having first entitlement to recover its out-of-pocket expenses
if the recovery is insufficient to reimburse both PARTIES for their out-of-pocket expenses. Any excess amount of such a recovery
shall be shared and distributed as follows: the PARTY initiating such action, shall retain seventy-five percent (75%) of such excess
amount and twenty-five percent (25%) paid to the non-initiating PARTY.

 

4.6 Concerns
regarding PATENT RIGHTS In the event COMPANY has concerns regarding the validity, patentability or enforceability of the PATENT RIGHTS,
COMPANY shall provide LICNESOR written notice of such concern. Within fourteen (14) days after receipt of such notice, a senior executive
officer of LICENSOR, and a senior executive officer of COMPANY shall meet in person or by teleconference and exchange written summaries
reflecting the nature and extent of the concern, and at this meeting they shall use their reasonable endeavors to resolve the dispute.
If, within a further period of thirty (30) days, or if in any event within ninety (90) days following initial receipt of the notice from
COMPANY, the concern has not been resolved, then the parties may pursue other dispute resolution mechanisms.

 

ARTICLE
5

OBLIGATIONS OF THE PARTIES

 

5.1 Reports.
COMPANY shall provide to LICENSOR the following written reports, which reports shall be Confidential Information of COMPANY, according
to the following schedules.

 

(a) COMPANY
shall provide calendar quarterly royalty reports, substantially in the format of Exhibit C and due within thirty (30) days of the
end of each calendar quarter following the FIRST COMMERCIAL SALE of a LICENSED PRODUCT. Royalty Reports shall disclose the amount of LICENSED
PRODUCT(S) sold, the total NET SALES of such LICENSED PRODUCT(S), and the running royalties due to LICENSOR as a result of NET SALES by
COMPANY, AFFILIATED COMPANIES and SUBLICENSEE(S) thereof. Payment of any such royalties due shall accompany such Royalty Reports.

 

(b) Until
such time as COMPANY, an AFFILIATED COMPANY or a SUBLICENSEE(S) has achieved a FIRST COMMERCIAL SALE of a LICENSED PRODUCT, or received
FDA market approval, COMPANY shall provide annual diligence reports, due within thirty (30) days of the end of every December following
the EFFECTIVE DATE of this Agreement. These diligence reports shall describe COMPANY’s, AFFILIATED COMPANY’s or any SUBLICENSEE(S)’s
technical efforts towards meeting its obligations under the terms of this Agreement, particularly its progress toward achieving the developmental
milestones set forth in Exhibit B and shall explain any delays experienced in achieving such milestones relative to the projected
dates for achievement set forth in Exhibit B.

 

(c) COMPANY
shall further provide in conjunction with the annual report due in January pursuant to 5.1(b) or the quarterly royalty report due in the
last calendar quarter of each calendar year pursuant to Paragraph 5.1(a), the following information:

 

(i) evidence of
insurance as required under Paragraph 10.4, or, a statement of why such insurance is not currently required; and

 

(ii) identification
of all AFFILIATED COMPANIES which have exercised rights pursuant to Paragraph 2.1, or, a statement that no AFFILIATED COMPANY has exercised
such rights;

 

(iii) identification
of (A) all SUBLICENSEE(S) with which COMPANY has entered into an agreement pursuant to the terms of Paragraph 2.2 and all (B) sublicensee(s)
of such SUBLICENSEE(S) with which such SUBLICENSEE(S) have entered into agreements pursuant to the terms of Paragraph 2.2, in each case
since the previous annual report; and

 

(iv) notice
of all FDA approvals of any LICENSED PRODUCT(S) obtained by COMPANY, AFFILIATED COMPANY or SUBLICENSEE, the patent(s) or patent application(s)
licensed under this Agreement upon which such product or service is based, and the commercial name of such product or service, or, in
the alternative, a statement that no FDA approvals have been obtained.

 

    9

     

    

 

5.2 Records.
COMPANY shall make and retain, for a period of three (3) years following the period of each report required by Paragraph 5.1(a), true
and accurate records, files and books of account containing all the data reasonably required for the full computation and verification
of sales and other information required in Paragraph 5.1(a). Such books and records shall be in accordance with generally accepted accounting
principles consistently applied. COMPANY shall permit the inspection of such records, files and books of account by LICENSOR’S agent
(the “Auditor”), which Auditor shall be a nationally recognized auditor acceptable to COMPANY, such acceptance not to be unreasonably
withheld, and subject to obligations of confidentiality and nonuse reasonably acceptable to COMPANY. Any such inspection shall occur during
regular business hours upon ten (10) business days’ written notice to COMPANY. Such inspection shall not be made more than once each calendar
year. All costs of such inspection shall be paid by LICENSOR, provided that if any such inspection shall reveal that an error has been
made resulting in an underpayment equal to five percent (5%) or more of any payment due to LICENSOR, the costs of such inspection shall
be borne by COMPANY. As a condition to entering into any such agreement, COMPANY shall include in any agreement with its AFFILIATED COMPANIES
or its SUBLICENSEE(S) which permits such party to make, use, sell or import the LICENSED PRODUCT(S), a provision requiring such party
to retain records of sales of LICENSED PRODUCT(S) and other information as required in Paragraphs 5.1(a) and this Paragraph 5.2 and permit
the Auditor to inspect such records as required by this Paragraph 5.2. All information and records made available to the Auditor pursuant
to this Paragraph 5.2 shall be deemed to be and treated as Confidential Information of COMPANY pursuant to Article 8.

 

5.3 Commercially
Reasonable Efforts. COMPANY shall exercise commercially reasonable efforts to develop and to introduce the LICENSED PRODUCT(S)
into the commercial market as soon as practicable, consistent with sound and reasonable business practice and judgment; thereafter,
until the expiration or termination of this Agreement, COMPANY shall endeavor to keep LICENSED PRODUCT(S) reasonably available to
the public. COMPANY shall also exercise commercially reasonable efforts to develop LICENSED PRODUCT(S) suitable for different
indications within the LICENSED FIELD, so that the PATENT RIGHTS can be commercialized as broadly and as speedily as good scientific
and business judgment would deem possible. Developmental milestones for a LICENSED PRODUCT are outlined in Exhibit B. Should
COMPANY fail to achieve the developmental milestones and COMPANY and LICENSOR fail to agree upon a mutually satisfactory revised
time line, LICENSOR shall be allowed to terminate this Agreement pursuant to Paragraph 9.2.

 

5.4 Other
Products. After clinical evidence has been provided in writing by LICENSOR to COMPANY demonstrating the practicality of a particular
market or use of PATENT RIGHTS within the LICENSED FIELD which is not being developed or commercialized by COMPANY, COMPANY shall either
provide LICENSOR with a reasonable development plan and start commercially reasonable efforts to develop in that particular market or
use or make commercially reasonable efforts to sublicense the particular market or use to a third party. If within six (6) months of such
notification by LICENSOR, COMPANY has not initiated such development efforts or initiated efforts to sublicense that particular market
or use, LICENSOR may terminate this license for such particular market or use. This Paragraph 5.4 shall not be applicable if COMPANY reasonably
demonstrates to LICENSOR that commercializing such LICENSED PRODUCT(S) or granting such a sublicense in said market or use would have
a substantial adverse effect upon the ability of COMPANY to market or sell the LICENSED PRODUCT(S) being developed or being sold by COMPANY.

 

5.5 Patent
Acknowledgement. COMPANY agrees that all packaging containing individual LICENSED PRODUCT(S) sold by COMPANY, AFFILIATED COMPANIES
and SUBLICENSEE(S) of COMPANY will be marked with the number of the applicable patent(s) licensed hereunder in accordance with each country’s
patent laws.

 

ARTICLE
6

REPRESENTATIONS

 

6.1 Duties
of the Parties. LICENSOR is an institute of research and education and not a commercial organization. Therefore, LICENSOR has no ability
to evaluate the commercial potential of any PATENT RIGHTS or LICENSED PRODUCT or other license or rights granted in this Agreement. It
is therefore incumbent upon COMPANY to evaluate the rights and products in question, to examine the materials and information provided
by LICENSOR and to determine for itself the validity of any PATENT RIGHTS, its freedom to operate, and the value of any LICENSED PRODUCTS
or other rights granted.

 

    10

     

    

 

6.2 Representations by
LICENSOR. LICENSOR warrants that it has good and marketable title to its interest in the PATENT RIGHTS with the exception of
certain retained rights of the United States Government, which may apply if any part of the research was funded in whole or in part
by the United States Government. LICENSOR does not warrant the validity of any patents or that practice under such patents shall be
free of infringement. EXCEPT AS EXPRESSLY SET FORTH IN THIS PARAGRAPH 6.2, COMPANY, AFFILIATED COMPANIES AND SUBLICENSEE(S) AGREE
THAT THE PATENT RIGHTS, ARE PROVIDED “AS IS”, AND THAT LICENSOR MAKES NO REPRESENTATION OR WARRANTY WITH RESPECT TO THE
PERFORMANCE OF LICENSED PRODUCT(S) INCLUDING THEIR SAFETY, EFFECTIVENESS, OR COMMERCIAL VIABILITY. LICENSOR DISCLAIMS ALL WARRANTIES
WITH REGARD TO PRODUCT(S) LICENSED UNDER THIS AGREEMENT, INCLUDING, BUT NOT LIMITED TO, ALL WARRANTIES, EXPRESSED OR IMPLIED, OF
MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE. NOTWITHSTANDING ANY OTHER PROVISION OF THIS AGREEMENT, LICENSOR ADDITIONALLY
DISCLAIMS ALL OBLIGATIONS AND LIABILITIES ON THE PART OF LICENSOR AND INVENTORS, FOR DAMAGES, INCLUDING, BUT NOT LIMITED TO, DIRECT,
INDIRECT, SPECIAL, AND CONSEQUENTIAL DAMAGES, ATTORNEYS’ AND EXPERTS’ FEES, AND COURT COSTS (EVEN IF LICENSORS HAVE BEEN ADVISED OF
THE POSSIBILITY OF SUCH DAMAGES, FEES OR COSTS), ARISING OUT OF OR IN CONNECTION WITH THE MANUFACTURE, USE, OR SALE OF THE
PRODUCT(S) LICENSED UNDER THIS AGREEMENT. COMPANY, AFFILIATED COMPANIES AND SUBLICENSEE(S) ASSUME ALL RESPONSIBILITY AND LIABILITY
FOR LOSS OR DAMAGE CAUSED BY A PRODUCT MANUFACTURED, USED, OR SOLD BY COMPANY, ITS SUBLICENSEE(S) AND AFFILIATED COMPANIES WHICH IS
A LICENSED PRODUCT(S) AS DEFINED IN THIS AGREEMENT.

 

ARTICLE
7

INDEMNIFICATION

 

7.1Indemnification.COMPANY,
AFFILIATED COMPANY and SUBLICENSEE(S) shall indemnify, defend with counsel reasonably acceptable to LICENSOR, and hold LICENSOR, the American
Lebanese Syrian Associated Charities, Inc. (ALSAC; a non- profit, 501(c)(3) corporation which supports ST. JUDE), their present and former
trustees, directors, governors, officers, INVENTORS of PATENT RIGHTS, agents, faculty, employees and students harmless as against any
claims, demands, damages, judgments, fees (including reasonable attorneys fees), expenses, or other costs arising from or incidental to
a breach of any representation, warranty or covenant made by COMPANY in this Agreement, any product liability or other lawsuit, claim,
demand or other action brought by a third party as a consequence of the practice of the PATENT RIGHTS by COMPANY, AFFILIATED COMPANY and
SUBLICENSEE(S), whether or not LICENSORS or said INVENTORS, either jointly or severally, are named as a party defendant in any such lawsuit
and whether or not LICENSOR or the INVENTORS are alleged to be negligent or otherwise responsible for any injuries to persons or property.
Practice of the PATENT RIGHTS covering the LICENSED PRODUCT(S) by an AFFILIATED COMPANY or an agent or a SUBLICENSEE(S) or a third party
on behalf of or for the account of COMPANY or by a third party who purchases LICENSED PRODUCT(S) from COMPANY, shall be considered COMPANY’s
practice of said PATENT RIGHTS for purposes of this Paragraph. The obligation of COMPANY to defend, indemnify and hold harmless as set
out in this Paragraph shall survive the termination of this Agreement, shall continue even after assignment of rights and responsibilities
to an AFFILIATE COMPANY or SUBLICENSEE, and shall not be limited by any other limitation of liability elsewhere in this Agreement.

 

ARTICLE
8

CONFIDENTIALITY

 

8.1 Confidentiality.
If necessary, the Parties will exchange information they consider to be confidential. The recipient of such information agrees to accept
the disclosure of said information, including but not limited to the terms of this Agreement and any reports or information provided by
COMPANY pursuant to Article 5 (“Confidential Information”). The recipient of Confidential Information agrees to employ all
reasonable efforts to maintain the Confidential Information secret and confidential, such efforts to be no less than the degree of care
employed by the recipient to preserve and safeguard its own confidential information. The Confidential Information shall not be disclosed
or revealed to anyone except employees of the recipient which employees (i) have a need to know the Confidential Information, (ii) are
subject to obligations of confidentiality and non-use substantially similar to those set forth in this Article 8, and (iii) have been
advised by the recipient of the confidential nature of the Confidential Information and that the Confidential Information shall be treated
accordingly.

 

    11

     

    

 

COMPANY may disclose Confidential Information to the extent
that such disclosure is:

 

		(A)	Required by Governmental Order. Made in response to a valid order of a court of competent jurisdiction
or other supra-national, federal, national, regional, state, provincial or local governmental or regulatory body of competent jurisdiction;
provided, however, that COMPANY shall first have given notice to LICENSOR and given LICENSOR a reasonable opportunity to quash such order
and to obtain a protective order requiring that the Confidential Information and documents that are the subject of such order be held
in confidence by such court or agency or, if disclosed, be used only for the purposes for which the order was issued; and provided further
that if a disclosure order is not quashed or a protective order is not obtained, the Confidential Information disclosed in response to
such court or governmental order shall be limited to that information which is legally required to be disclosed in response to such court
or governmental order;

 

		(B)	Required by Law. Otherwise required by law; provided, however, that COMPANY shall (a) provide LICENSOR
with reasonable advance notice of and an opportunity to comment on any such required disclosure, (b) if requested by LICENSOR, seek confidential
treatment with respect to any such disclosure to the extent available, and (c) use good faith efforts to
incorporate the comments of LICENSOR in any such disclosure or request for confidential treatment;

 

		(C)	Required by Regulatory Authority. Made by COMPANY to the regulatory authorities as required in
connection with any filing, application or request for regulatory approval; provided, however, that reasonable measures shall be taken
to assure confidential treatment of such information;

 

		(D)	Required by Agreement. Made by COMPANY, in connection with the performance of this Agreement, to
AFFILIATED COMPANIES, SUBLICENSEES, research parties, employees, consultants, representatives or agents, each of whom prior to disclosure
must be bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Paragraph 8.1; or

 

		(E)	Required by Certain Third Parties. Made by COMPANY to existing or potential acquirers or merger
candidates; existing or potential SUBLICENSEES; investment bankers; existing or potential investors, venture capital firms or other financial
institutions or investors for purposes of obtaining financing; or AFFILIATED COMPANIES, each of whom prior to disclosure must be bound
by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Paragraph 8.1.

 

The obligations of this
Paragraph shall also apply to AFFILIATED COMPANIES and/or SUBLICENSEE(S) that are provided such Confidential Information by COMPANY.
LICENSOR’S, COMPANY’s, AFFILIATED COMPANIES’, and SUBLICENSEES’ obligations under this Paragraph shall extend until
three (3) years after the termination of this Agreement.

 

    12

     

    

 

8.2 Exceptions.
The recipient’s obligations under Paragraph 8.1 shall not extend to any part of the Confidential Information:

 

		a.	that can be demonstrated to have been in the public domain or publicly known and readily available to
the trade or the public prior to the date of the disclosure; or

 

		b.	that can be demonstrated, from written records to have been in the recipient PARTY’s possession
or readily available to the recipient PARTY from another source not under obligation of secrecy to the disclosing PARTY prior to the disclosure;
or

 

		c.	that becomes part of the public domain or publicly known by publication or otherwise, not due to any unauthorized
act by the recipient PARTY; or

 

		d.	that is demonstrated from written records to have been developed by or for the receiving PARTY without
reference to Confidential Information disclosed by the disclosing PARTY.

 

		e.	that is required to be disclosed by law, government regulation or court order.

 

8.3 Right to Publish.
LICENSOR may publish manuscripts, abstracts or the like describing the PATENT RIGHTS and inventions contained therein provided
Confidential Information of COMPANY, as defined in Paragraph 8.1, is not included or without first obtaining written approval from
COMPANY to include such Confidential Information. Otherwise, LICENSOR and the INVENTORS shall be free to publish manuscripts and
abstracts or the like without prior approval. The text of the proposed manuscripts, abstracts or the like containing any COMPANY
Confidential Information must be provided to COMPANY at least sixty (60) days prior to the date of submission for consideration for
manuscripts, abstracts or the like in order to provide COMPANY an opportunity to comment on such proposed manuscripts, abstracts or
the like and determine if COMPANY Confidential Information is disclosed therein. In the event that COMPANY so comments prior to such
intended submission date, LICENSOR shall (x) delay submission of such manuscripts, abstracts or the like thirty (30) days beyond
such intended submission date and, during such thirty (30) day period, engage in good faith discussion of such comments with
COMPANY, and (y) consider in good faith the modification of such proposed manuscripts, abstracts or the like pursuant to such
comments. Upon the request of COMPANY, LICENSOR shall remove COMPANY Confidential Information from any proposed manuscripts,
abstracts or the like.

 

ARTICLE
9

TERM & TERMINATION

 

9.1 Term.
The term of this Agreement shall commence on the EFFECTIVE DATE and shall continue, in each country, until the date of expiration of the
last to expire VALID CLAIM included within PATENT RIGHTS in that country.

 

9.2 Termination
by Either PARTY. This Agreement may be terminated by either COMPANY or LICENSOR, in the event that the other PARTY (a) files or has
filed against it a petition under the Bankruptcy Act, makes an assignment for the benefit of creditors, has a receiver appointed for it
or a substantial part of its assets, or otherwise takes advantage of any statute or law designed for relief of debtors or (b) fails to
perform or otherwise breaches any of its obligations hereunder, if, following the giving of notice by the terminating PARTY of its intent
to terminate and stating the grounds therefor, the PARTY receiving such notice shall not have cured such failure or breach within sixty
(60) days. In no event, however, shall such notice or intention to terminate be deemed to waive any rights to damages or any other remedy
which the PARTY giving notice of breach may have as a consequence of such failure or breach.

 

    13

     

    

 

9.3 Termination
by COMPANY. COMPANY may terminate this Agreement and the license granted herein, for any reason, upon giving LICENSOR thirty (30)
days written notice.

 

9.4 Obligations
and Duties upon Termination. If this Agreement is terminated, the PARTIES shall be released from all obligations and duties imposed
or assumed hereunder to the extent so terminated, except as expressly provided to the contrary in this Agreement. Upon termination, each
PARTY shall cease any further use of the Confidential Information received from the other PARTY. Termination of this Agreement, for whatever
reason, shall not affect the obligation of any PARTY to make any payments for which it is liable prior to or upon such termination. Termination
shall not affect LICENSOR’S right to recover unpaid royalties, fees, reimbursement for patent expenses, or other forms of financial
compensation incurred prior to termination. Upon termination, COMPANY shall submit a final royalty report to LICENSOR and any royalty
payments (if after first commercial sale of LICENSED PRODUCTS), fees, unreimbursed patent expenses and other financial compensation due
to LICENSOR shall become immediately payable. Furthermore, upon termination of this Agreement, all rights in and to the PATENT RIGHTS
shall revert immediately to LICENSOR at no cost to LICENSOR. Upon termination of this Agreement, any SUBLICENSEE(S) shall become with
such SUBLICENSEE(S)’ agreement a direct licensee of LICENSOR, provided that LICENSOR’S obligations to SUBLICENSEE(S) are no
greater than LICENSOR’S obligations to COMPANY under this Agreement. COMPANY shall provide written notice of such to each SUBLICENSEE(S)
with a copy of such notice provided to LICENSOR.

 

ARTICLE 10

MISCELLANEOUS

 

10.1 Use
of Name or Logo. COMPANY, AFFILIATED COMPANIES and SUBLICENSEE(S) shall not use the name or logo
of LICENSOR or American Lebanese Syrian Associated Charities, or any of their constituent parts, such as St. Jude Children’s Research
Hospital or ALSAC any contraction thereof or the name of INVENTORS in any advertising, promotional, sales literature or fundraising documents
without prior written consent from an authorized representative of ST. JUDE, as applicable. LICENSOR will not use publicly for publicity,
promotion, or otherwise, any logo, name, trade name, service mark, or trademark of COMPANY, its AFFILIATED COMPANIES, and SUBLICENSEE(S)
or any simulation, abbreviation, or adaptation of the same, or the name of any COMPANY employee or agent, without COMPANY’s prior, written,
express consent. COMPANY, AFFILIATED COMPANIES and SUBLICENSEE(S) shall allow at least seven (7) business days notice of any proposed
public disclosure for LICENSOR’S review and comment or to provide written consent. LICENSOR
shall allow at least seven (7) business days notice of any proposed public disclosure for COMPANY, AFFILIATED
COMPANIES or SUBLICENSEE(S) review and comment or to provide written consent.

 

10.2 No
Partnership. Nothing in this Agreement shall be construed to create any agency, employment, partnership, joint venture or similar
relationship between LICENSOR and COMPANY other than that of a licensor/licensee. Neither LICENSOR nor COMPANY shall have any right or
authority whatsoever to incur any liability or obligation (express or implied) or otherwise act in any manner in the name or on the behalf
of the other, or to make any promise, warranty or representation binding on the other.

 

10.3 Notice
of Claim. Each, LICENSOR and COMPANY, shall give the other or its representative immediate notice of any suit or action filed, or
prompt notice of any claim made, against them arising out of the performance of this Agreement or arising out of the practice of the INVENTIONS
licensed hereunder.

 

10.4 Insurance.  Prior
to initial human testing or FIRST COMMERCIAL SALE of any LICENSED PRODUCT(S) as the case may be and thereafter so long as LICENSED
PRODUCTS are being sold in any particular country COMPANY and SUBLICENSEES shall establish and maintain appropriate insurance
coverage in the minimum amount of five million dollars ($5,000,000) per claim, with an aggregate of ten million dollars
($10,000,000), to cover any liability arising from COMPANY’S indemnification obligations under Article 7 above with respect to
such human testing or commercial sale of LICENSED PRODUCT. Prior to initial human testing or FIRST COMMERCIAL SALE of any LICENSED
PRODUCT(S) as the case may be and thereafter so long as LICENSED PRODUCTS are being sold in any particular country, COMPANY and
SUBLICENSEES shall establish and maintain, in each country in which COMPANY, an AFFILIATED COMPANY or SUBLICENSEE(S) shall test or
sell LICENSED PRODUCT(S), product liability or other appropriate insurance coverage in the minimum amount of five million dollars
($5,000,000) per claim. COMPANY will annually present evidence, in the form of a statement in the annual report to LICENSOR that
such coverage is being maintained. Upon LICENSOR’S request, COMPANY will furnish LICENSOR with a Certificate of Insurance of each
insurance policy obtained. LICENSOR and ALSAC shall be listed as additional insureds in COMPANY’s said insurance policies. If such
insurance is underwritten on a ‘claims made’ basis, COMPANY agrees that any change in underwriters during the term of
this Agreement and thereafter so long as LICENSED PRODUCTS are being sold will require the purchase of ‘prior acts’
coverage to ensure that coverage will be continuous throughout the term of this Agreement and thereafter so long as LICENSED
PRODUCTS are being sold.

 

    14

     

    

 

10.5 Governing
Law and Venue.  In the event that legal action is brought arising from this Agreement, it shall be brought in Memphis, Tennessee and
shall be governed by the laws of the State of Tennessee, without regard to conflicts of law provisions thereof.

 

10.6 Notice.
All notices or communication required or permitted to be given by either PARTY hereunder shall be deemed sufficiently given if mailed
by registered mail or certified mail, return receipt requested, or sent by overnight courier, such as Federal Express, to the other PARTY
at its respective address set forth below or to such other address as one PARTY shall give notice of to the others from time to time hereunder
or if sent by email to the other PARTY as provided below. Mailed notices shall be deemed to be received on the third business day following
the date of mailing. Notices sent by overnight courier shall be deemed received the following business day.

 

	If to COMPANY:	 	 
	 	 	 
	 	 	Blue Water Vaccines
	 	 	2014 Courtland Avenue
	 	 	Cincinnati, OH 06830
	 	 	Attn.: Joseph Hernandez
	 	 	Phone:
	 	 	Email:jhernandez@bluewatervaccines.com
	 	 	 
	 	 	With a copy to:
	 	 	Erin Henderson
	 	 	6308 SW 35th Way
	 	 	Gainesville, FL 32608
	 	 	404-405-6315
	 	 	ehenderson@bluewatervaccines.com
	 	 	 
	If to ST. JUDE:	 	 
	 	 	 
	 	 	Office of Technology Licensing
	 	 	Attn. Associate Director
	 	 	St. Jude Children’s Research Hospital
	 	 	262 Danny Thomas Place
	 	 	Memphis, Tennessee
	 	 	Phone: (901) 595-2751
	 	 	Shawn.hawkins@stjude.org

 

    15

     

    

 

10.7 Compliance
with All Laws. In all activities undertaken pursuant to this Agreement, LICENSOR and COMPANY covenant and agree that each will in
all material respects comply with such Federal, state and local laws and statutes, as may be in effect at the time of performance and
all valid rules, regulations and orders thereof regulating such activities.

 

10.8 Successors
and Assigns. Neither this Agreement nor any of the rights or obligations created herein, except for the right to receive any remuneration
hereunder, may be assigned by either PARTY, in whole or in part, without the prior written consent of the other PARTIES, except that either
PARTY shall be free to assign this Agreement in connection with any sale of substantially all of its assets without the consent of the
other, but shall provide written notice of such assignment within thirty (30) days of its occurrence. This Agreement shall bind and inure
to the benefit of the successors and permitted assigns of the PARTIES hereto.

 

10.9 No
Waivers; Severability. No waiver of any breach of this Agreement shall constitute a waiver of any other breach of the same or other
provision of this Agreement, and no waiver shall be effective unless made in writing. Any provision hereof prohibited by or unenforceable
under any applicable law of any jurisdiction shall as to such jurisdiction be deemed ineffective and deleted herefrom without affecting
any other provision of this Agreement. It is the desire of the PARTIES hereto that this Agreement be enforced to the maximum extent permitted
by law, and should any provision contained herein be held by any governmental agency or court of competent jurisdiction to be void, illegal
and unenforceable, the PARTIES shall negotiate in good faith for a substitute term or provision which carries out the original intent
of the PARTIES.

 

10.10 Entire
Agreement; Amendment. COMPANY and LICENSOR acknowledge that they have read this entire Agreement and that this Agreement, including
the attached Exhibits constitutes the entire understanding and contract between the PARTIES hereto and supersedes any and all prior or
contemporaneous oral or written communications with respect to the subject matter hereof. It is expressly understood and agreed that (i)
there being no expectations to the contrary between the PARTIES hereto, no usage of trade, verbal agreement or another regular practice
or method dealing within any industry or between the PARTIES hereto shall be used to modify, interpret, supplement or alter in any manner
the express terms of this Agreement; and (ii) this Agreement shall not be modified, amended or in any way altered except by an instrument
in writing signed by both of the PARTIES hereto.

 

10.11 Delays
or Omissions. Except as expressly provided herein, no delay or omission to exercise any right, power or remedy accruing to any PARTY
hereto, shall impair any such right, power or remedy to such PARTY nor shall it be construed to be a waiver of any such breach or default,
or an acquiescence therein, or in any similar breach or default be deemed a waiver of any other breach or default theretofore or thereafter
occurring. Any waiver, permit, consent or approval of any kind or character on the part of any PARTY of any breach or default under this
Agreement, or any waiver on the part of any PARTY of any provisions or conditions of this Agreement, must be in writing and shall be effective
only to the extent specifically set forth in such writing. All remedies either under this Agreement or by law or otherwise afforded to
any PARTY, shall be cumulative and not alternative.

 

    16

     

    

 

10.12 Force
Majeure. If a PARTY fails to fulfill its obligations hereunder (other than an obligation for the payment of money), when such failure
is due to an act of God, or other circumstances beyond its reasonable control, including but not limited to fire, flood, civil commotion,
riot, war (declared and undeclared), revolution, epidemics, terrorism, earthquake or embargoes, then said failure shall be excused for
the duration of such event and for such a time thereafter as is reasonable to enable the parties to resume performance under this Agreement,
provided however, that in no event shall such time extend for a period of more than one hundred eighty (180) days.

 

10.13 Further
Assurances. Each PARTY shall, at any time, and from time to time, prior to or after the EFFECTIVE DATE of this Agreement, at reasonable
request of the other PARTY, execute and deliver to the other such instruments and documents and shall take such actions as may be required
to more effectively carry out the terms of this Agreement.

 

10.14 Survival.
All representations, warranties, covenants and agreements made herein and which by their express terms or by implication are to be performed
after the execution and/or termination hereof, or are prospective in nature, shall survive such execution and/or termination, as the case
may be. This shall include Paragraphs 3.8 (Late Payments), 5.2 (Records), and Articles 6, 7, 8, 9, and 10.

 

10.15 No
Third Party Beneficiaries. Nothing in this Agreement shall be construed as giving any person, firm, corporation or other entity, other
than the PARTIES hereto and their successors and permitted assigns, any right, remedy or claim under or in respect of this Agreement or
any provision hereof.

 

10.16 Headings.
Article headings are for convenient reference and not a part of this Agreement. All Exhibits are incorporated herein by this reference.

 

10.17 Counterparts.
This Agreement may be executed in counterparts, each of which shall be deemed an original and all of which when taken together shall be
deemed but one instrument.

 

IN WITNESS WHEREOF, this Agreement
shall take effect as of the EFFECTIVE DATE when it has been executed below by the duly authorized representatives of the parties.

 

	BLUE WATER VACCINE, INC.	 	ST. JUDE CHILDREN’S RESEARCH HOSPITAL, INC.
	 	 	 
	/s/ Joseph Hernandez	 	/s/ J. Scott Elmer
	Name: 	 Joseph Hernandez	 	Name: 	 J. Scott Elmer
	Title:	Chief Executive Officer 	 	Title:	Director, Office of Technology Licensing
	 	 	 
	January 27, 2020	 	 
	(Date)	 	(Date)

 

EXHIBIT A. LICENSE FEE & ROYALITIES.

EXHIBIT B. DEVELOPMENTAL MILESTONES & MILESTONE
PAYMENTS

EXHIBIT C. SALES & ROYALTY REPORT FORM.

 

    17

     

    

 

EXHIBIT
A

 

LICENSE FEE & ROYALTIES

 

1.
License Fee: The initial license fee due under Paragraph 3.1 within thirty (30) days of the EFFECTIVE DATE is fifteen thousand US
dollars [***].

 

2.
Annual Maintenance Fee: The annual maintenance fee pursuant to Paragraph 3.2 is ten thousand US dollars ($10,000) per year, beginning
on the first anniversary of the effective date of the license, provided the annual maintenance fee shall be waived if all developmental
milestones scheduled for completion before the annual fee is due according to Exhibit B have been achieved.

 

3.
Royalties: The running royalty rate payable under Paragraph 3.3 is four percent (4%).

 

In the event COMPANY is required to enter into one
or more third party license agreements to practice Patent Rights, the royalty payments due LICENSOR may be reduced by a percentage equal
to half of that paid to such third party. However, in no event shall the milestone payments due to LICENSOR be reduced by more than one
half of the original royalty percentage.

 

SUBLICENSE CONSIDERATION: COMPANY shall pay
LICENSOR Fifteen percent (15%) of any SUBLICENSE CONSIDERATION.

 

    18

     

    

 

EXHIBIT B

 

DEVELOPMENTAL MILESTONES &
MILESTONE PAYMENTS

 

1.
Developmental Milestones: Developmental Milestones by COMPANY for a LICENSED PRODUCT in accord with Paragraph 5.3 are as follows:

 

	 	Complete IND enabling study	 	2020
	 	Initiate animal toxicology study	 	last half 2020
	 	File IND	 	first half 2021
	 	Complete PHASE I CLINICAL TRIAL	 	first half of 2022
	 	Commence PHASE II CLINICAL TRIAL	 	2024
	 	Commence PHASE III CLINICAL TRIAL	 	2026
	 	Regulatory approval, US or foreign equivalent	 	2026

 

2.
Milestone Payments: The Milestone Payments payable under Paragraph 3.5 are as follows:

 

	 	Upon Commencement of PHASE III CLINICAL TRIAL	 	[***]
	 	Upon regulatory approval, US or foreign equivalent	 	[***]
	 	Upon FIRST COMMERCIAL SALE	 	[***]

 

“Commence” or “Commencement”
of either a PHASE I, PHASE II or PHASE III CLINCIAL TRIAL shall mean the dosing of the first patient in such PHASE I, PHASE II, or PHASE
III CLINICAL TRIAL.

 

    19

     

    

 

EXHIBIT C

 

SALES & ROYALTY REPORT

 

FOR LICENSE AGREEMENT BETWEEN
BLUE WATER VACCINES AND

ST. JUDE CHILDREN’S RESEARCH HOSPITAL DATED

 

 

 

FOR PERIOD OF _________ TO __________

 

TOTAL ROYALTIES DUE FOR THIS PERIOD $
______

 

	
     

    PRODUCT ID
	
     

    PRODUCT OR SERVICE

    NAME
	
     

    *ST. JUDE REFERENCE
	1st COMMERCIAL SALE DATE	TOTAL GROS S SALES	
     

    TOTAL REDUCTIONS
	
     

    TOTAL NET SALES
	
     

    ROYALTY RATE
	
     

    AMOUNT DUE

	 	 	
    SJ-11-0001

    SJ-18-0045
	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 

 

* Please provide the ST. JUDE Reference Number or Patent
Reference

 

This report format is to be used
to report quarterly royalty statements to ST. JUDE. It should be placed on COMPANY letterhead and accompany any royalty payments due for
the reporting period. This report shall be submitted even if no sales are reported.

 

 

    20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}]]